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ABSTRACT OF DISSERTATION 
 
 
ENGINEERING PROTEINS WITH UNIQUE CHARACTERISTICS FOR 
MOLECULAR DIAGNOSTICS AND BIOSENSORS 
Proteins possess a broad range of structural and functional properties and, 
therefore, can be employed in a variety of biomedical applications. While a good number 
of protein-based biosensing systems and biosensors for target analytes have been 
developed, the search for versatile, highly sensitive and selective sensors with long term 
stability able to provide fast detection of target analytes continues to be a challenge.  To 
that end, we now report the design and development of modified proteins with tailored 
characteristics and their further utilization in the development of biosensing systems.  
We take advantage of binding proteins that undergo a change in conformation 
upon binding to their respective target ligand analytes for the development of highly 
selective biosensing systems. The first class of binding proteins that was explored for this 
purpose was antibodies.  A non-canonical site in the variable region of a monoclonal 
antibody was tagged with a fluorescent probe to sense the binding of analyte to its 
corresponding antigen-binding site. The strategy employed for designing antibody-
sensing molecules is universal as it can be employed for sensing any biomolecule of 
interest provided that there is an available antibody against the target ligand analyte.  
In a second strategy, we utilized designer glucose recognition proteins (GRPs) 
that were prepared by incorporation of unnatural amino acids in the glucose/galactose 
binding protein (GBP) of Escherichia coli and its truncated fragments. By taking 
advantage of the global incorporation method, we were able to fine-tune the binding 
affinity and thermal stability of the proteins, thus, allowing for the development of a 
reagentless fluorescence based fiber optic glucose biosensor capable of monitoring 
glucose in the hypoglycemic, normal, and hyperglycemic range, as well as in the 
hypothermic and hyperthermic temperature range.  
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CHAPTER ONE 
 
 
INTRODUCTION 
 
 
Proteins are heteropolymers of amino acids with a wide array of functions and 
properties. Emerging challenges in medicine, discovery science, and engineering present 
an ongoing demand for modified proteins with enhanced functionality and properties. For 
many years scientists have relied on nature for producing proteins that evolved into new 
ones with different characteristics. A new field of engineering known as protein 
engineering emerged due to advances in the field of DNA technology in the 1970s. 
Protein engineering provides the basis for the design and construction of new or 
improved proteins. Protein engineering has provided new insights into protein structure 
and function.  The principles of gene modification set forth by the capability of preparing 
synthetic oligonucleotides in the early 1970s,1, 2 allowed for the first report on site-
directed mutagenesis to modify DNA by Smith and co-workers.3  However, the actual 
use of site-directed mutagenesis to introduce changes at known sites in structural genes 
with the aim of studying and modifying protein function was not reported until the early 
1980s.4 Specifically, mutants of tyrosyl-tRNA synthetase and β-lactamase were among 
the first proteins to be prepared by these methods and analyzed.5 However, another 
stumbling block in the field of protein engineering was its inability to modify proteins 
specifically at predetermined positions as the knowledge of three-dimensional structure 
was still vague. The advent of new technologies that enabled solving protein structures by 
X-ray crystallography in a nearly routine manner proved to be crucial in advancing the 
field of protein engineering.  Recent advancements in interactive graphics and computer 
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modeling softwares along with their use by biological chemists and biotechnologists have 
stimulated knowledge-based design of proteins, thus providing better understanding of 
the structure and function of proteins.  
 Today, scientists can design and create proteins using a plethora of genetic-based, 
posttranslational, and chemical modification methods.  Figure 1 shows the steps involved 
in designing and creating functional proteins. The first step in designing a new protein 
involves knowledge of the original protein structure to be modified. This information is 
provided by the X-ray crystal structure or 2-D NMR of the protein to be modified, which 
is prepared by expression, purification, and characterization of its functions followed by 
its crystallization. A thorough study of the original protein structure gives an insight 
about the locations within the original protein that can be altered to endow the protein 
with target modifications. The protein is then modified at the genetic level or by chemical 
means, and subsequently evaluated to assess whether the target characteristics have been 
incorporated. The cycle continues as the new protein can again be studied and modified 
using the same methods. 
 In this dissertation work, various protein engineering methods are employed and 
discussed. However, the main focus remains the engineering of designer proteins by 
global incorporation of unnatural amino acids and by chemical modification of 
immunoglubulins via photolabeling.  Specifically, designer proteins for glucose sensing 
were developed by global incorporation of unnatural amino acids within the 
Galactose/Glucose Binding Protein (GBP) of E. coli. These designer glucose recognition 
proteins (GRPs) with improved stability and activity were then incorporated into a 
hydrogel network, which 
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Figure 1.1 Schematic showing the steps involved in the design and engineering of novel 
proteins. Figure adapted from Blundell, et al, Phil. Trans. R. Soc. Lond. B 324, 448, 
1989. 
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served as the sensing material in fiber optic biosensors for glucose. Designer antibodies 
were prepared by photolabeling at an unconventional site within the variable region of 
the antibody, and utilized for developing universal biosensing systems for various 
biomolecules. 
 
Mutagenesis 
 
The properties and functions of proteins can be altered at the genetic level. The 
process for generating amino acid coding changes at the DNA level is called 
mutagenesis. These changes in the amino acids can be generated in a site-directed or 
random manner. With the availability of X-ray crystallographic structures of proteins, it 
is possible to determine which amino acids in a protein can be changed to attain a specific 
property. Mutations can either be point mutations, wherein one amino acid is replaced by 
another, or deletion mutations in which an amino acid is deleted from the amino acid 
sequence of a protein, or insertion mutations where an amino acid is inserted in the amino 
acid sequence. However, if the amino acids to be changed in order to alter the properties 
or functions of a protein are not known, then random mutagenesis can be carried out. 
This approach has two advantages. First, detailed information about the function of 
amino acids in the protein to be altered is not required. Secondly, this approach results in 
an array of protein mutants with potentially interesting properties. Methods to create 
random mutants include XL1-Red competent cells, error-prone PCR and degenerate 
oligonucleotides-Pfu (DOP).6 XL1-Red cells are engineered E. coli with DNA repair 
deficiency. In this method the plasmid bearing the DNA of interest is transformed into 
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the cells and mutations occur in each round of replication. In error-prone PCR the 
polymerase has high error rate. During amplification mutations are introduced by altering 
the ratio of nucleotides and the concentration of divalent cations.7 DOP mutagenesis 
involves the use of two degenerate oligonucleotides as primers. The position of mutation 
can be controlled by adjusting the ratios and position of degenerate nucleotides during the 
synthesis of degenerate oligonucleotides.  
 Point and deletion mutations can lead to the construction of proteins with new 
properties. Point mutations have been utilized in several proteins to introduce amino 
acids for covalent attachment of fluorophores. Hence, this protein engineering technique 
can be used to integrate optical signal transduction functions directly into proteins. This 
method has been used for developing fluorophore labeled binding protein biosensors for 
several analytes, including glucose, amino acids, anions, cations and dipeptides.8 A 
fluorescent biosensor family was constructed by mutating several periplasmic binding 
proteins to covalently attach environment sensitive fluorophores to the proteins.8 Single 
cysteine mutations were performed at desired locations in the protein, which allowed 
covalent attachment of environment sensitive fluorophores in or near the ligand binding 
pocket of the protein. The biosensors can detect the presence of the ligand/analyte, which 
is measured as a dose-dependent change in the fluorescence of the fluorophore upon 
ligand binding.8-10 Besides fluorescent reporter molecules, several other molecules can be 
covalently attached to mutated proteins for immobilization purposes.  
 Thermostability of proteins can be improved by site-directed mutagenesis. Point 
mutations have been engineered in the yeast enzyme triosephosphate isomerase to replace 
two different asparagines with threonine and isoleucine. Converting the asparagines to 
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threonine and isoleucine enhanced the thermostability of the enzyme. However, replacing 
an asparagine with aspartic acid resulted in reduced thermostability of the protein.11 
Thermostability of proteins can also be enhanced by adding disulfide bonds within the 
structure of the protein, which can be achieved by introducing cysteine residues via site-
directed mutagenesis. T4 lysozyme in its native form has two cysteines, neither of which 
is involved in a disulfide bond. The melting temperature of T4 lysozyme is 41.9 °C. It has 
been reported that introducing cysteines that are involved in the formation of disulfide 
bonds enhances the thermal stability of T4 lysozyme. The results demonstrated that the 
thermal stability increases as the number of disulfide bonds increases, with the most 
thermostable mutant being the one with the largest number of disulfide bonds (Table 
1.1).12 
The catalytic activity of proteins can also be modified by site-directed 
mutagenesis. This has been proved by engineering two point mutations in tyrosyl-tRNA 
synthetase of Bacillus stearothermophilus. One mutation, Thr51-Ala51 was done to get 
rid of the hydroxyl group and the other, Thr51-Pro51 was performed to distort the local 
polypeptide backbone. Both mutations increased ATP binding activity in the enzyme. 
The mutant with Pro51 was found to bind ATP 100-fold stronger than the native 
enzyme.13  
Furthermore, mutagenesis has been utilized to engineer proteins for therapeutic 
purposes. For example, insulin has been engineered through site-directed mutagenesis to 
create rapid acting (lispro, aspart and glulisine) and long acting (glargine and detemir) 
insulin analogs.14 The rapid acting insulin analogs were constructed by replacing or 
switching one or two amino acids. These mutations in insulin reduce the tendency to 
7 
 
Table 1.1 Melting temperature of wild type and engineered mutants of T4 lysozyme. 
Adapted from Matsumura, et al, Nature 342, 291-293, 1989. 
	 	
Enzyme 
No. of disulfide 
bonds 
Tm (°C) 
Wild type 0 41.9 
3C-54T 1 46.7 
D3-97/9-164 2 57.6 
D9-164/21-142 2 58.9 
T3-97/9-164/21-142 3 65.5 
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form hexamers, thus facilitating rapid absorption. The long acting insulin analogs were 
obtained by substitution or deletion of specific amino acids. These changes resulted in a 
shift in the isoelectric point of insulin from 5.4 to 6.7, which prolongs its dissociation at 
physiological pH conditions. Another strategy to engineer proteins for therapeutic 
purposes is the development of catalytic antibodies. Antibodies are proteins that are used 
by the immune system to identify and neutralize foreign agents. However, mutagenesis 
has enabled the development of catalytic antibodies that function as enzymes and 
catalyze reactions. Some of the potential therapeutic applications include detoxification 
after accidental exposure to insecticides,15 prevention of cocaine addiction and 
overdose,16, 17 and prodrug activation in cancer treatment.18 
 
Fusion Proteins 
 
Partial or full protein sequences can be joined together via recombinant DNA 
technology resulting in fusion or hybrid proteins. These proteins can have partial or full 
functions or characteristics of the constituent proteins. Fusion proteins have extensively 
been used to study interactions between proteins. Additionally, a binding protein can be 
fused to an inherently fluorescent protein, such as the green fluorescent protein (GFP) 
from the jellyfish Aequorea victoria, to develop protein-based sensing systems. Upon 
binding to the analyte, the target binding protein undergoes a change in the conformation, 
which can be detected as a dose-dependent change in the fluorescence of the reporter 
protein, GFP. Furthermore, fluorescent fusion proteins have been used to study the 
location, movement and degradation of proteins in living cells.19 Another application of 
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fusion proteins is to aid in the purification of proteins via affinity chromatography. A 
short sequence of amino acids, such as histidines, are fused to either the N- or C-terminus 
of a protein allowing for its purification by nickel affinity chromatography; for example, 
in this dissertation work a six histidine sequence was inserted at the C-terminus of the 
gene encoding the glucose binding protein for purification via nickel affinity. Small 
peptides20 or antibody fragments21 can also be fused to proteins for purification purposes. 
For example, fusion of antibody fragments to proteins enables purification via 
interactions with protein A. Fusion protein technology has been employed to develop 
biosensing systems for peptides,20 drugs, zinc and heme, among others. An octapeptide 
was fused to GFP in order to develop a fluorescence binding assay for the peptide. The 
immunoassay was based on the sequential binding of the free octapeptide and GFP 
labeled octapeptide to anti-octapeptide antibodies on a solid surface.22 A zinc sensor was 
developed by fusing histidine tags at each end of a fusion protein comprised of the 
enhanced cyan and enhanced yellow fluorescent proteins joined together by a linker. 
Since the hexahistidine tags undergoe dimerization in the presence of zinc, fluorescence 
resonance energy transfer occurs between the two fluorescent protein domains, thus 
resulting in the ratiometric detection of zinc in nM ranges.23 In another example, 
cytochrome b562, a heme-binding protein, was fused to the N-terminus of the enhanced 
green fluorescent protein (EGFP) to create a heme sensor. The detection of hemin was 
based on the fluorescence quenching due to energy transfer between EGFP and 
cytochrome b562 in the presence of hemin.
24 
 Split protein technology, which is employed to study protein-protein 
interactions25, 26 and protein-nucleotide interactions, is a step further in the field of protein 
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engineering.27 The split protein methodology includes one and two component systems. 
A one component system consists of two fragments of a reporter protein attached to two 
peptides or nucleotides. The two component system has been exemplified by fragmenting 
GFP and attaching the two inactive fragments to two leucine zippers. The leucine zippers 
come together via non-covalent interactions, bringing the two fragments of GFP together, 
hence producing fluorescence.28  When two fragments of a reporter protein are attached 
to the two termini of a binding protein in a one component system, the binding of the 
ligand to the binding protein results in a conformation change that brings the two 
fragments of the reporter protein closer, hence producing a signal. This approach can be 
utilized to develop biosensing systems for various biomolecules by inserting the sequence 
of a biomolecule binding protein within the sequence of a reporter protein. 
Conformational changes in maltose binding protein (MBP) have been studied using the 
one component split methodology. Two fragments of GFP were attached to the N- and C-
terminus of MBP. Upon binding to maltose, the two fragments of GFP were brought 
together and resulted in changes in fluorescence. The changes in fluorescence in response 
to maltose were detected in a concentration and time dependent manner.29 This sensing 
strategy is also referred to as molecular switches,30, 31 and has been utilized for inserting 
MBP,29 GBP32 (Figure 1.2), and calmodulin33 within split reporter proteins such as GFP, 
aequorin, and EGFP, respectively. The split protein methodology allows for two 
functionally and structurally unrelated proteins to be integrated, thus combining their 
characteristics; hence, it can prove to be an important tool for designing molecular 
sensors for analytical and therapeutic applications.34  
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Figure 1.2 Schematic of a protein switch showing the components (GBP, AEQ 
fragments) and triggers (glucose, calcium ions, coelenterazine) that result in switching 
from the “off” to “on” mode.  
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Minimalist Proteins 
Proteins are macromolecules comprised of hundreds of amino acids. However, 
only a fraction of the protein structure or amino acid sequence in a protein is required for 
maintaining a specific biological activity. Hence, efforts have been made to create a 
minimum portion of a protein structure required to retain the desired function. For 
example, in an enzyme or a binding protein the substrate or ligand binds to an active site 
consisting of a specific sequence of amino acids; however, the amino acid sequence of 
the rest of the protein helps in maintaining the required structure of the active site.35 The 
truncation of proteins to generate protein fragments that contain the amino acid sequence 
essential for maintaining the protein biological function has been explored in our lab. 
GBP is one example of such proteins subjected to truncation. 
The galactose/glucose binding protein (GBP) from E. coli is a periplasmic protein 
involved in bacterial chemotaxis and active transport of glucose and galactose.36 GBP is a 
monomer with a molecular weight of 33 kDa, consists of 309 amino acids, and binds to 
glucose and galactose present in μM ranges.37 GBP is ellipsoidal in shape and consists of 
two globular domains held together by three peptide strands referred to as the hinge 
region.10 The two domains have a core of six strand β-sheet flanked on both sides by two 
or three helices.38 In the open form (Figure 1.3), when glucose is not bound, the two 
domains are far apart and the ligand binding site is deep within the cleft and accessible to 
solvent. On the other hand, in the closed form (Figure 1.3) glucose is bound in the cleft 
between the two domains and the ligand binding site is solvent-inaccessible, which 
results in the formation of an extensive network of hydrogen bonds between the polar 
residues of the binding site and the sugar.39 The binding of glucose is accompanied by a 
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Figure 1.3 Crystal structure of GBP without glucose (A, open form) and with glucose (B, 
closed form). 
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conformational change of the protein at the hinge region. The bound sugar is stabilized 
within the binding pocket by a series of interactions, including hydrogen bonds, van der 
Waals interactions and salt bridges. Upon binding to the sugar, 13 strong hydrogen bonds 
are formed between the sugar and the protein, involving eight polar side chains of GBP 
distributed between the two domains and a water molecule. Additionally, the 
glucopyranose ring is stacked on both sides with aromatic residues. The presence of 
glucose bound to GBP has been found to increase the stability of the protein structure and 
restore the cooperativity of temperature-induced transitions.40 In addition to the sugar 
binding site, GBP also has a calcium binding site in the C-terminal domain. The calcium 
binding site is constituted by a nine residue (134-142) loop.41 
GBP was truncated at both the N- and the C-terminus generating protein fragments. 
Three fragments of GBP were thus obtained. The largest one had amino acids 14 through 
296, the second fragment had 14 through 256, and the smallest one had 87 through 271. 
The smallest fragment did not bind to glucose; hence, it lost its activity upon truncation, 
suggesting that the amino acids removed from the protein sequence were essential for 
glucose binding. However, the two larger fragments of the full length GBP (Figure 1.4) 
showed glucose binding activity.42 This observation suggested that the full length amino 
acid sequence is not necessary for maintaining the activity of GBP. Therefore, utilization 
of the minimalist strategy allows for the creation of smaller functional proteins. The 
minimalist protein strategy can also be utilized to study folding of the protein and its 
active site.43  
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Figure 1.4 Crystal structure of GBP with glucose. The red portions in the structure 
indicate the parts of the amino acid sequence that have been eliminated. A: GBP 
fragment with amino acids 14 through 296, B: GBP fragment with amino acids 14 
through 256.42  
A  B
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Incorporation of unnatural amino acids 
 
A key advancement in the field of protein-based biosensors is the design of 
proteins with improved binding selectivity, specificity and affinity for their ligands, with 
enhanced stability of the protein. Protein engineering methods are generally based on 
chemical and genetic methods. A more recent, less studied method of engineering 
proteins involves the incorporation of unnatural amino acids in place of natural amino 
acids in proteins, either  
at a particular site (site-specific) or throughout the protein (global). This is a challenging 
method as it plays with the natural fidelity and proof reading mechanism that living 
organisms are endowed with.  Nature has provided 20 natural amino acids that are vital 
for the existence of organisms. Replacing the natural amino acids with unnatural amino 
acids might result in the production of undesired or incorrect proteins, which can lead to 
cell death. However, emerging techniques and new methods have allowed expanding the 
genetic code beyond the one nature has provided.  
Expanding the genetic code via incorporation of unnatural amino acids allows 
exploring the structure and function of proteins by manipulating the amino acid 
backbone. Also, this method allows for the tailoring or tuning of properties and functions 
of proteins. For example, if leucine in a protein is replaced by an unnatural analogue of 
leucine, such as fluoroleucine, then the change in the structure of the protein can be 
studied. Fluorine and hydrogen have similar van der Waals radii; therefore, hydrogen can 
easily be replaced with fluorine in amino acids, producing minimal steric perturbation in 
proteins. However, high electronegative and hydrophobic characteristics endow proteins 
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with distinct properties. Several fluorinated amino acids, such as, fluorovaline, 
fluoroleucine, fluoroisoleucine, fluorophenylalanine, and fluoroproline have successfully 
been incorporated into the structure of proteins.44 Besides providing an insight into the 
structure of a protein, incorporation of unnatural amino acids allows for introducing 
chemical scission sites and sites for photoaffinity labeling. It also enables site-specific 
conjugation and immobilization. A variety of methods for the incorporation of unnatural 
amino acids in proteins have been developed, which include solid phase peptide 
synthesis, semi-synthesis, in vitro site-specific incorporation, in vivo site-specific 
incorporation, and global incorporation. All of these methods will be discussed in the 
following sections. In our efforts towards improving the activity and stability of GBP we 
utilized the global incorporation of unnatural amino acids into the structure of GBP. 
 
 
Solid phase peptide synthesis 
 
One of the most used methods for incorporation of unnatural amino acids is solid 
phase peptide synthesis. This is a synthetic method for producing peptides or proteins that 
are difficult to express in bacteria or to introduce unnatural amino acids in peptides. This 
method employs the carboxyl group of one amino acid for coupling with the amino group 
of another amino acid, while protecting the amino or carboxyl group of amino acids not 
involved in peptide bond formation. In peptide synthesis an amino acid is bound to a 
resin via the carboxyl group and the amino group is protected. The amino group is then 
deprotected and reacted with the carboxyl group of another amino acid having the amino 
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group protected. This method involves repetitive cycles of deprotecting, coupling and 
washing. The synthesized peptide remains covalently attached to the solid support until 
cleaved by anhydrous hydrogen fluoride or trifluoroacetic acid. Two important protecting 
groups used for protecting the α-amino group are Fmoc (9-
fluorenylmethyloxycarbonyl)45, 46 and t-Boc (tert-butoxycarbonyl).47, 48 A variety of solid 
supports, such as, polystyrene or polyacrylamide resins can be used. This method is well 
standardized and automated; however, it has a drawback, that is, only small peptides 
comprising up to 100 amino acids can be synthesized. This chemical method can also be 
used for incorporating unnatural amino acids in peptides. However, the peptide produced 
may not fold properly or show the desired activity. The desired activity of proteins may 
be achieved by post-translational modification of the protein within the cell. However, 
the desired activity of protein cannot be obtained using the chemical synthesis of 
peptides. The demand for bigger peptides or proteins still remains; to that end, semi-
synthesis of proteins can be performed. 
Semi-synthesis of proteins involves chemical ligation of either two naturally 
existing smaller peptides or two peptides synthesized via solid phase peptide synthesis or 
one natural and one synthesized peptide. A major advancement in this field was the 
chemoselective linkage49 of a peptide containing an amino-terminal cysteine with a 
peptide containing a carboxy-terminal thioester, attained by the initial 
transthioesterification followed by S,N-shift to produce a native amide bond. Hence, this 
method can be used for generating recombinant proteins.  Amino-terminal cysteines can 
be introduced in proteins using proteases,50 while a thioester can be introduced into a 
recombinant protein by fusion to an intein. The peptide with carboxy-terminal cysteine 
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then reacts with the protein thioester by native chemical ligation, resulting in a semi-
synthetic protein. This method is known as expressed protein ligation (EPL).51, 52 This 
method allows the generation of bigger peptides/proteins and somewhat overcomes the 
limitations posed by post-translational modification of proteins. A drawback of this semi-
synthesis method is that it requires the introduction of an N-terminal cysteine or the 
presence of cysteine within the structure of the protein, which in some cases may perturb 
the structure or activity of the protein. The incorporation of unnatural amino acids at 
desired locations within proteins is also limited when using EPL methods as the unnatural 
amino acid can only be introduced in the synthetic part of the peptide. Thus, the need to 
incorporate unnatural amino acids without any location restrictions has been achieved by 
exploiting the natural biological machinery that the cells use for manufacturing proteins.  
 
 
Site-specific incorporation of unnatural amino acids 
 
The fidelity of the genetic code depends upon the interaction of codon-anticodon 
and the acylation of tRNA with the proper amino acid by aminoacyl-tRNA synthetases 
(aaRSs). Thus, changing the genetic code requires a tRNA for a specific codon and a 
method of acylating the tRNA with an unnatural amino acid. Nature has provided 64 
three base codons in the standard genetic code. Three of these three base codons, namely, 
UAG (amber), UAA (ochre) and UGA (opal) are referred to as stop codons or nonsense 
codons as they signal the termination of translation. The amber codon is the least used 
stop codon in E. coli, and a number of efficient ‘suppressor’ tRNAs are known.53 The 
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suppressor tRNAs are tRNAs from certain organisms that have the capability to ‘read 
through’ a stop codon. Additionally, the presence of the amber suppressors in some E. 
coli strains does not significantly affect cell growth rates.54 
 Schultz and Chamberlin have reported in vitro incorporation of unnatural amino 
acids by “nonsense suppression” strategy. Nonsense suppression involves the use of 
nonsense codons and suppressor tRNAs. The first step towards incorporation of unnatural 
amino acids via this method is the construction of aminoacylated suppressor tRNA. 
Hecht and coworkers have constructed a suppressor tRNA by the condensation of the 3' 
end of an E. coli truncated tRNA and an acylated dinucleotide in the presence of T4 RNA 
ligase, hence resulting in an aminoacyl-tRNA (aatRNA) charged with an unnatural amino 
acid.55, 56  This methodology has been further improved by Schultz57 and Sisido.58 
Dougherty and coworkers have been successful in incorporating unnatural amino 
acids into proteins expressed in Xenopus oocytes via the nonsense suppression method. 
The oocyte is coinjected with the modified mRNA encoding for the target protein and the 
aatRNA is chemically acylated with an unnatural amino acid. This results in the 
expression of the protein containing the unnatural amino acid on the surface of the 
oocyte. This methodology has enabled a detailed study of the structure-function 
relationships of ion channels and the incorporation of biophysical probes.59  
Further, Schultz and coworkers have developed an alternative to the nonsense 
supression method for incorporating unnatural amino acids into proteins in vivo. This 
method (Figure 1.5) utilizes a novel tRNA/aaRS pair for each unnatural amino acid to be 
incorporated. The aaRS is engineered such that it can only recognize the unnatural amino 
acid and proficiently acylate the tRNA. The tRNA/aaRS pair should be orthogonal to the 
21 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Site-specific unnatural amino acid incorporation method. The specific site on 
the protein’s gene is first mutated to TAG. The genes encoding for the orthogonal 
tRNA/aminoacyl-tRNA synthetases are cotransformed into E. coli with the genes for the 
TAG-mutated protein.   
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host organism, meaning that the aaRS must not recognize endogenous tRNAs and the 
suppressor tRNA cannot be a substrate for endogenous aaRSs. The most commonly used 
tRNA/aaRS pair has originated from Methanococcus jannaschii. The tRNA/aaRS pair 
from M. jannaschii has been used to incorporate various unnatural amino acids, such as 
photoactivatable amino acids60 and keto-containing amino acids,61 into proteins. Several 
other orthogonal tRNA/aaRS pairs have been proposed to suppress nonsense codons in 
eukaryotic cells, including mammalian cell lines.62 Schultz and coworkers have 
efficiently incorporated five amino acids with high fidelity in the genetic code of 
Saccharomyces cerevisiae by utilizing a unique orthogonal tRNA/aaRS pair originated 
from E. coli.63  
Site-specific incorporation of unnatural amino acids allows for the precise 
positioning of the desired unnatural amino acid. However, the nonsense suppression 
approach for incorporation of unnatural amino acids suffers from the limitation that a 
maximum of two unnatural amino acids can be incorporated in a protein at a time, due to 
the availability of two nonsense codons. Sisido and coworkers have overcome this 
limitation by using extended codons and frame shift suppression. However, if these 
extended codons are read as a three base codon by an endogenous tRNA, the reading 
frame will be shifted by one base. This will eventually result in a premature encounter 
with a stop codon and early termination of protein synthesis, thereby resulting in a 
truncated protein. Several four and five base codons have been used to incorporate 
unnatural amino acids in proteins in E.coli.64-67 
The in vivo method has been used to incorporate a wide variety of unnatural 
amino acids in proteins. These include chemically reactive amino acids containing 
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functional groups, such as, ketones and photoreactive groups capable of covalent 
bonding, activation via photocages, and photoisomerization upon irradiation with UV 
light. Fluorescent amino acids have also been incorporated. An amino acid analogue of 
prodan, an environment-sensitive fluorophore, has been successfully incorporated in 
yeast proteins.68 Incorporation of fluorinated amino acids in proteins causes minimal 
perturbation of the protein structure because the van der Waals radii of fluorine and 
hydrogen are similar. Incorporation of trifluorleucine in coiled-coil proteins has shown to 
enhance stability. The 4-iodo-l-phenylalanine residue can be used for the chemoselective 
modification of proteins. Rowe et al. have recently incorporated four unnatural 
phenylalanines (bromo, iodo, amino and methoxy derivatives) in place of tyrosine at 
position 82 in aequorin. Aequorin is a bioluminescent protein with an emission 
wavelength at 473 nm. The incorporation of unnatural phenylalanine resulted in a 
spectral shift of up to 44 nm in aequorin.69 
 
 
Global incorporation of unnatural amino acids 
 
Site-specific incorporation of unnatural amino acids enables the study of protein 
structure and function. It also allows the introduction of new functions in the protein by 
adding novel functional groups. However, the number of unnatural amino acids that can 
be introduced in a protein via site-specific incorporation is very limited. The global 
incorporation method allows the incorporation of unnatural amino acids throughout the 
protein; hence, it helps in better understanding the structural and functional properties of 
a protein. Global incorporation of β-selenolo[3,2-b]pyrrolyl-L-alanine in the small 
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protein barstar allows for solving phase problems in protein X-ray crystallography.70 
Global incorporation involves the replacement of a single natural amino acid at all 
positions within the protein by its unnnatural amino acid analogue. For example, if an 
unnatural derivative of lysine is incorporated in a protein via the global method, then all 
the lysines in the protein are theoretically replaced by the unnatural analogue. This 
method requires that the unnatural analogue is structurally very similar to the natural 
amino acid, so that it is readily accepted by the natural tRNA in the genetic/synthetic 
machinery of the organism. An unnatural amino acid that differs considerably from the 
natural amino acid might lead to no or partial incorporation in the protein. Another 
requirement is the use of an auxotrophic host strain. An auxotrophic strain is a cell strain 
that cannot grow in the absence of a particular amino acid. Therefore the growth of such 
strains requires the addition of that particular amino acid in the growth medium. This 
method utilizes the natural machinery of the cells for protein synthesis and does not 
require special tRNAs or ribosomes. To incorporate an unnatural amino acid globally, the 
auxotrophic strain for the amino acid that will be replaced by its unnatural analogue is 
grown in a growth medium enriched with all 20 amino acids. The cells are then harvested 
by centrifugation and then washed thoroughly to get rid of the growth medium. The cells 
are then grown again in a medium that is enriched with all amino acids except for the one 
that needs to be replaced by its unnatural analogue, followed by the addition of the 
unnatural analogue. This method of global incorporation is known as the “medium shift 
method.” The possibility of tuning the properties of proteins via global incorporation was 
proven by incorporating norleucine in place of methionines in a cytochrome, which 
increased the peroxygenase activity by two-fold70. The hydrophobicity and spectral 
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properties of barstar were tuned by replacing natural tryptophans with 
aminotryptophans.71 In another example 5-hydroxytryptophan and 7-azatryptophan were 
incorporated in staphylococcal nuclease. An incorporation efficiency of 98% was 
reported. The secondary structure was found to be unaltered by the incorporation, but the 
stability of the proteindecreased upon incorporation of unnatural analogues.72 Bae and 
coworkers incorporated unnatural tryptophans in the green fluorescent protein (GFP), 
thus shifting the emission spectra and achieving a “gold” variant of GFP.73 In another 
example the global method was used to incorporate six unnatural amino acids, p-amino-
L-phenylalanine, 3-amino-L-tyrosine, 5-hydroxy-L-tryptophan, 3-fluoro-L-tyrosine, 5-
fluoro-L-tryptophan, and 6-fluoro-L-tryptophan, into the structure of aequorin to study 
their effects on the bioluminescence properties of the photoprotein.  A 54 nm shift in the 
emission maximum of aequorin, when compared to the native aequorin, with a variety of 
coelenterazine analogues was observed.74 Thus, global incorporation of unnatural amino 
acids, such as tryptophan analogues, might facilitate altering the structure of proteins and, 
consequently, their properties. 
 
 
Binding Proteins 
 
Binding proteins bind to a specific ligand or class of ligands. These proteins are 
ubiquitous and, within the cell, the binding of the ligand by the proteins is generally 
accompanied by the transport of the bound ligand in or out of the cell. For example, GBP 
is involved in the active transport of glucose across the cell membrane from the 
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environment into the cell.75 Binding proteins have been classified on the basis of the 
ligands they bind. Examples include glucose binding proteins (e.g., GBP, as mentioned 
previously), calcium binding proteins (e.g., calmodulin, described in a later section), 
nucleotide (DNA/RNA) binding proteins, and sulfate binding proteins. Binding proteins 
are also classified on the basis of the mechanism utilized for binding the ligand. An 
interesting class of binding proteins is that of the so-called hinge-motion binding 
proteins. Hinge-motion binding proteins undergo a change in the conformation, 
consisting of the bending of two protein domains around a hinge region, upon binding to 
their ligands.76 Many hinge-motion binding proteins are found in the periplasm of 
bacterial cells and are involved in the transport of molecules and ions across the cell 
membrane.77 These periplasmic binding proteins consist of two globular domains that are 
connected by a hinge region. The binding site is found at the interface of the two 
domains.78 The ligand is bound to various residues in the binding site by hydrogen bonds, 
van der Waals interactions,79, 80 π-interactions81 or ionic interactions.82 Upon binding to 
the ligand the periplasmic proteins adopt a ligand-bound (closed) conformation and, in 
the absence of the ligand, the protein adopts a ligand-free (open) conformation. These 
two forms interconvert through a large bending motion around the hinge. An example of 
such hinge-motion binding proteins is GBP, which is described in a previous section. 
Protein engineers and bioanalytical chemists have harnessed the change in binding 
protein conformation upon ligand binding to develop biosensing systems for several 
analytes, as previously reported under the section “Mutagenesis”. Another class of 
binding proteins includes antibodies or immunoglobulins, which bind to a wide range of 
molecules, such as, proteins, nucleotides, drugs, pathogens, other antibodies, etc. 
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Antibodies as binding proteins 
 
Antibodies or immunoglobulins are glycoproteins that are produced by plasma cells in 
response to an immunogen or antigen. Antibodies are found in the blood and other body 
fluids of vertebrates. The basic structure of antibody consists of two heavy chains (50-70 
kDa) and two light chains (~30 kDa) linked by disulfide bonds (Figure 1.6). Both heavy 
and light chains comprise constant and variable regions. Each heavy chain consists of one 
variable (VH) and three or four constant regions (CH1, CH2, CH3, CH4) depending upon the 
antibody isoytype. CH1 and CH2 are held together by a hinge region which allows 
flexibility between the two arms of a “Y” shaped antibody. Carbohydrates are attached to 
the CH2 region in most antibodies; however, in some cases they may also be attached at 
different locations. The antigen binding site resides between the variable regions of the 
light and heavy chains. The variable region is further divided into hypervariable regions 
(HV) and framework regions (FR). Most of the variability in the amino acid sequence of 
the variable region resides in the HV regions. HV regions are also called 
complementarity determining regions (CDRs). The HV regions form a direct contact with 
the antigen’s surface. The FR regions form a β-sheet structure which serves as a scaffold 
to hold the HV regions in position to make contact with the antigen. Antibody fragments 
produced by proteolytic digestion have been used for elucidating structure/function 
relationships in antibodies. Upon digestion with papain, the immunoglobulin molecule is 
cleaved at the hinge region generating two Fab fragments, each consisting of the light 
chain and the VH and CH1 domains of the heavy chain, and one Fc fragment consisting of 
the remaining constant domains of the heavy chain. Fab is involved in antigen binding. 
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Figure 1.6 Structure of antibody 
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Fc (so named because it can be crystallized easily) carries out the effector functions. The 
digestion with pepsin leads to the formation of F(ab')2, containing the two antigen 
binding sites, and to the cleaving of the Fc fragment into smaller peptides. 
Immunoglobulins can be divided into five classes based on the differences between the 
amino acid sequences in the constant regions of the heavy chains. These classes are IgG, 
IgA, IgM, IgD and IgE. Further, the light chains can be classified as κ or λ chains, based 
on the amino acid sequence in the constant region of the light chains. IgG are monomers 
and are the most versatile immunoglobulins, capable of performing all the functions of an 
immunoglobulin molecule. IgG are the major antibody in serum and the only antibody 
that crosses the placenta. IgM mostly exist as pentamers. They are the first class of 
antibody to appear in the serum after exposure to an antigen and the first to be produced 
in the fetus. IgA are found in external secretions such as saliva, tears, bronchial mucus 
and intestinal mucus. IgD and IgE exist as monomers. IgE bind to basophils and are 
involved in allergic reactions.83 
            Antibodies are divided into two types based on their specificity to antigens. 
Monoclonal antibodies recognize a single, specific epitope of an antigen, while 
polyclonal antibodies recognize various sites on an antigen. Monoclonal antibodies are 
usually produced by immunizing a mouse or a rabbit against the antigen of interest to 
stimulate the production of antibodies. The antibody forming cells are then isolated from 
the mouse’s spleen. These cells are then fused with mouse myeloma cells; the resulting 
cells are called hybridomas. Each hybridoma produces large quantities of identical 
antibody molecules. Polyclonal antibodies are produced by immunization of an animal, 
such as mouse, rabbit or goat. When the animal is injected with the antigen, the B-
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lymphocytes produce the polyclonal antibodies, which are collected from the animal 
blood serum.  
Antibodies have been used for several years for the detection of their 
corresponding antigens. Antibodies labeled with reporter groups form the basis of 
immunoassays. Immunoassay is an analytical technique for quantitative measurements of 
target compounds, which found numerous applications in clinical and biomedical 
diagnostics as well as environmental analysis. The ability of antibodies to form 
complexes with the corresponding antigens in a highly specific manner results in the 
great specificifty/selectivity of immunoassays. The most common type of immunoassay 
in clinical analysis is the enzyme linked immunosorbent assay (ELISA). ELISA can be 
used to detect specific antigens or antibodies present in the sample.  In sandwich-type 
ELISA, a solid surface (such as polystyrene) is coated with a solution of antibody against 
the target antigen (capture antibody), and the sample to be analyzed is then added. After 
incubation, the bound antigen is either detected by the addition of an enzyme-labeled 
detection antibody specific for the captured antigen (Direct Sandwich) or by first adding 
the antigen-specific antibody followed by addition of an enzyme-labeled secondary 
antibody (Indirect Sandwich). The final step is the addition of a chromogenic enzyme 
substrate, which produces a color whose intensity is determined by absorbance 
measurements using a spectrophotometer. The label enzyme is usually conjugated to the 
antibody via chemical coupling, which leads to random attachment of the enzyme to the 
reactive amino acid side chains of the antibody. This nonspecific coupling of the enzyme 
to the antibody can lead to various degrees of antibody denaturation or loss of antibody 
activity or binding ability. To overcome this drawback a method that allows more 
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specific attachment of enzymes or other molecules to antibodies is required.   
Kohler and co-workers have reported the presence of a novel site in the variable 
antibody domain involving invariant residues, which binds purine containing nucleotide 
photoaffinity probes with high affinity.84 This novel site can be utilized for site-specific 
labeling of antibodies. The nucleotide/nucleoside affinity site is formed by parts of both 
the light and heavy chains within the variable domain of the immunoglobulin. A 
computer model of the antibody with adenosine diphosphate (ADP) in the 
unconventional site was constructed by Kohler and his co-workers (figure 1.7).84 The 
model shades light on the biochemical aspects of the interaction between the purine and 
the site in the Ig molecule.84  Figure 1.7 also shows the structure and location of the 
nucleotide with respect to the antigen binding site.84 The antigen binding site is 
unaffected by the binding of the ADP molecule in the hydrophobic pocket that forms this 
unconventional site and that is located below the antigen binding site.84, 85 The purine ring 
is held in the hydrophobic pocket via stacking, while the phosphate groups and the ribose  
are exposed to the solvent between the variable domains of the heavy and light chains of 
the Ig.84, 85 The phosphate groups can thus be tethered to molecules like biotin, metal 
chelates, antisense oligonucleotides, and peptides without affecting the Ig antigen binding 
site. The purine ring is held between the rings of Trp 103 (in the Ig heavy chain) and Pro 
44 (in the Ig light chain) by nonspecific stacking interactions.84, 85 The fact that these 
heterocyclic amino acids are highly conserved in most antibodies, and the successful 
photolabeling of various antibodies suggest that most antibodies can be labeled at this 
unconventional site.84, 85 Upon photolysis a covalent bond can be formed between the 
azido group of the purine ring and the hydroxyl group of Tyr 36 in the light chain as they 
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Figure 1.7 Computer generated model of the Fv region of the Ig with the inserted ADP. 
A: The loops facing the top are the CDRs with the antigen binding site. The red and green 
represent the light chain and heavy chain, respectively. B: Interaction of ADP with the 
residues Trp-H103, Tyr-L36, and Asp-H101 in the heavy and light chains of the Ig 
molecule.84 
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are in close proximity.84, 85 A similar interaction of the purine ring of the nucleotide probe 
with the residues Asp 101 or Glu 100 in the heavy chain has been observed in other 
antibodies.84, 85Immunoprecipitation experiments have shown that the average number of 
probes attached to each antibody molecule is approximately two, and that each of the two 
arms of the antibody have been labeled with the probe.84 It has been demonstrated that a 
biotin molecule can be attached to ATP via the ribose ring or the γ phosphate.85, 86 These 
biotin conjugates can then bind to the unconventional site of an antibody in a similar 
manner as the binding of ADP to the unconventional site.85, 86 There is no steric 
hindrance to the antigen binding site of the antibody by this interaction with the 
biotinylated ATP. This photobiotinylation is performed under mild, physiological 
conditions, and is quick due to the high affinity of the unconventional site for the 
nucleotide/nucleoside probes.85, 86 Since this process involves photoactivated chemical 
crosslinking, it can be controlled by time and intensity of UV exposure. Also, no residual 
chemically reactive groups are obtained, as a result of photochemical crosslinking, which 
would need to be removed.86 Therefore, this conserved unconventional site of antibodies 
could be utilized to incorporate signal transduction for the development of biosensing 
systems. These biosensing systems would be advantageous over ELISA in that they 
would be ready to use and would require no washing steps. Another advantage of the 
novel unconventional binding site is its utilization to tether molecules of biological and 
medical interest to antibodies via coupling to the phosphate groups or the ribose in the 
nucleotide moiety. We have utilized this novel binding site of antibody to develop a 
universal biosensing system for biomolecules by covalently attaching a nucleotide 
fluorescent analog to the nucleotide binding site. 
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Incorporation of engineered proteins in hydrogels 
 
 
Hydrogels are three dimensional covalently crosslinked, hydrophilic, water 
insoluble polymers that swell upon absorbing large amounts of water. Hydrogels have a 
wide variety of functions related to their swelling, mechanical, permeation, surface and 
optical properties. These properties make hydrogels suitable for an array of potential 
applications in the fields of medicine,87, 88 agriculture89 and biotechnology.90 In addition, 
hydrogels can undergo a change in response to an environmental cue or to a change in 
environmental conditions. Such stimuli sensitive hydrogels are referred to as “smart” or 
responsive hydrogels. Various stimuli-responsive hydrogels that respond to pH,91, 92 
temperature,93, 94 ion concentration,95 electric potential,96 and solvent composition97 have 
been studied. Stimuli-responsive hydrogels have been utilized in molecular switches, 
sensors, drug delivery devices, specialized separation systems and artificial muscles. 
“Smart” or responsive hydrogels have been made employing protein domains and 
polypeptides that fold into three dimensional structures with distinct functions. Protein 
engineering allows for the manipulation of DNA sequences encoding protein domains or 
peptides and, therefore, allows control over the structure and function of these peptides or 
domains. Incorporating such engineered proteins within hydrogels can enable 
manipulation of the properties of the hydrogel. An example of incorporation of such a 
genetically engineered protein into stimuli-responsive hydrogels has been demonstrated 
in our lab.98 In this system, calmodulin, a calcium binding protein, was selected as the 
biological recognition element in the smart hydrogel. Calmodulin undergoes a large 
conformational change upon binding calcium, certain peptides and phenothiazines. 
Calmodulin undergoes two conformational changes: in the presence of calcium it 
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assumes a “dumbbell” conformation, and in the presence of phenothiazines it goes from 
the “dumbbell” shape to a more constrictive conformation. A unique cysteine was 
introduced at the C-terminus of calmodulin by site-directed mutagenesis. This was done 
to attach an allylamine moiety to the free sulfhydryl residue in the protein. Allylamine 
allows oriented immobilization in hydrogels. Further, an amine derivative of 
phenothiazine was reacted with N-succinimidylacrylate to form a polymerizable 
phenothiazine. The hydrogel was then synthesized by free radical polymerization of 
allylamine-calmodulin, polymerizable phenothiazine, acrylamide and N,N’-
methylenebisacrylamide. It was observed that in the absence of Ca2+ the hydrogel swelled 
due to the release of immobilized phenothiazine from the calmodulin binding site and to 
the change in the conformation of calmodulin, which modifies the hydrophobic surface of 
the protein, thus altering the water uptake of the hydrogel (figure 1.8). However, in the 
presence of Ca2+, the phenothiazine was bound to the protein as the phenothiazine 
binding site was accessible. This creates non-covalent crosslinking in the polymer 
network, shrinking the hydrogel to its original size. 
Stimuli-responsive hydrogels find extensive applications in development of drug 
delivery systems. An example of such systems is that of glucose sensitive hydrogels for 
insulin delivery systems. Ishihara et al. developed a glucose responsive hydrogel to 
control the release of insulin in response to glucose variations.99 This system consisted of 
a copolymer membrane of N,N-diethylaminoethyl methacrylate and 2-hydroxypropyl 
methacrylate combined with a cross-linked polyacrylamide membrane. Glucose oxidase 
was immobilized within the hydrogel. Glucose oxidase is an enzyme that converts 
glucose to gluconic acid. In this system glucose diffuses in the membranes and is
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Figure 1.8 A schematic showing  swelling and shrinking of calmodulin containing 
hydrogel in absence and presnece of calcium. Figure reprinted by permission from Nature 
Publishing Group Ehrick, J. D. et al. Nat Mater 4, 298-302. 
 
 
 
 
 
 
 
 
37 
 
oxidized by glucose oxidase. The resulting gluconic acid lowers the pH in the membrane 
causing the membrane to swell due to the ionization of amine groups, thereby enhancing 
the permeability of the membrane to insulin (figure 1.9). Hence, permeation of insulin 
through the membrane is dependent on the concentration of glucose.  
In another study an antigen responsive hydrogel was developed by Miyata et al. 
utilizing chemically engineered antibody and antigen.100 In this system the antigen, rabbit 
IgG, and the antibody, goat anti-rabbit IgG, were chemically modified by coupling with 
N-succinimidylacrylate to introduce vinyl groups in both the antigen and the antibody. 
The vinyl antibody was copolymerized with acrylamide to create a polymerized antibody 
that acts as a linear chain in the hydrogel. The hydrogel was then prepared by 
polymerization of vinyl antigen, acrylamide, N,N’-methylenebisacrylamide as a 
crosslinker, in the presence of polymerized vinyl antibody. In the presence of free antigen 
the antigen- antibody hydrogel shows swelling. The swelling mechanism was explained 
as follows: in the presence of free antigen in the solution containing the antigen-antibody 
hydrogel, the dissociation of antigen-antibody bonds grafted to the network is induced by 
the free antigen as a result of the affinity of the antibody for the free antigen being 
stronger than that for the antigen attached to the hydrogel. The dissociation of antigen-
antibody bonds in the hydrogel decreases the crosslinking, thus causing the hydrogel to 
swell.  
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Figure 1.9 pH Sensitive hydrogel with glucose oxidase immobilized within the hydrogel. 
The hydrogel swells as glucose binds to glucose oxidase and is converted to gluconic 
acid, allowing insulin permeation. Figure adapted from Ishihara, K, et al, Polymer 
Journal 16, 625-631 (1984). 
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Incorporation of Biomaterials into Sensing Devices 
 
As shown in the previous section the integration of proteins with polymers has led 
to the fabrication of protein-based biomaterials. The incorporation of biomaterials into 
various platforms has led to the design of devices for a number of applications, including 
sensing, drug delivery, and clinical diagnostics. Protein biochips are composed of 
functional protein microarrays immobilized on a solid substrate (glass or silicone). A 
variety of chips have been designed, including 3D surface, nanowell and plain glass 
chips. The proteins are either directly immobilized on the solid substrate or captured in 
polyacrylamide or agarose gel and then immobilized on the solid substrate.101  Protein 
biochips find extensive applications in immunoassays,102 diagnosis,103 and drug 
discovery.104 ProteinChip technology has been utilized to profile and compare protein 
expression in normal and disease states in the areas of cancer, infectious disease and 
toxicology.105 
Nanomaterials are materials that incorporate structures having dimensions in the 
range 1-100 nm.106 Many properties of nanomaterials are size-dependent. Nanomaterials 
are classified on the basis of their morphology as nanotubes, nanowires, nanoparticles 
(also referred to as quantum dots), and sheet-like two-dimensional structures.107 A wide 
variety of biosensing devices based on nanomaterials have been investigated. A highly 
sensitive electrochemical biosensor for cholesterol has been reported, wherein cholesterol 
oxidase (ChOx) has been immobilized on well-crystallized flower-shaped ZnO structures 
composed of hexagonal-shaped ZnO nanorods. These nanorods are then immobilized on 
gold electrodes. The nanorods based biosensor exhibited a linear dynamic range from 
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1.0-15.0 μM and low detection limits.108 In another example, a glucose biosensor was 
developed by entrapping glucose oxidase (GOD) in a poly(o-aminophenol) (POAP) film 
for immobilization of the enzyme on a glassy carbon electrode modified with boron-
doped carbon nanotubes. The biosensor exhibited high sensitivity, low detection limits 
(3.6 μM), a short response time of 6 s, satisfactory anti-interference ability, and good 
stability as the POAP film, which is a non-conducting film, acts as a barrier to prevent 
electrode fouling from hydrogen peroxide and glucose.109 
Another interesting example of integration of hybrid materials and devices is 
provided by microelectromechanical systems (MEMS). These are very small mechanical 
devices driven by electricity. MEMS devices usually range from 20 μm to mm in size. In 
a sensor application, an antibody biorecognition element was immobilized on a MEMS 
cantilever. Binding of the corresponding antigen resulted in a change in the mass which 
was detected as a change in the frequency of a resonating circuit fabricated as a part of 
the cantilever structure.110 In another example, a MEMS thermal biosensor for 
monitoring metabolites was developed. This sensor consisted of a polymer microfluidic 
structure integrated with a silicon-based thermal biochip. The enzymes specific for a 
particular metabolite analyte were immobilized on microbeads in the microfluidic 
platform.111 
A further example of incorporation of biospecific elements in sensing devices is 
represented by fiber optic based sensors, which will be discussed in the following section. 
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Fiber Optic Biosensors 
 
A fiber optic biosensor is defined as “a biosensor that employs an optical fiber or 
optical fiber bundle as a platform for the biological recognition element, and as a conduit 
for excitation light and/or the resultant signal”.112  Fiber optic biosensors can be classified 
according to either the type of bioreceptor element or the signal transduction method. 
Some important signal transduction methods include optical, electrochemical, mass 
sensitive and thermometric methods. The biological components employed in fiber optic 
biosensors can be enzymes, antibodies or antigens, nucleic acids, whole cells or 
biomimetic receptors. A fiber optic biosensor can be further classified as:113 
 Intrinsic sensor – the interaction with the analyte occurs within an element of the 
optical fiber. 
 Extrinsic sensor – the optical fiber is used to couple light to and from the region 
where the light beam is influenced by the measurement. 
Optical fibers transmit light based on the principle of total internal reflection (TIR) 
(Figure 1.10). An optical fiber is formed by a core with a refractive index n1 and a 
cladding with a refractive index n2. When a ray of light strikes at the boundary of core 
and cladding a part of light is refracted and a part of it is reflected. If the refractive index 
of the core is greater than the refractive index of the cladding, i.e., n1˃n2 and the angle of 
incidence is larger than the critical angle, then the light is totally reflected internally and 
propagated through the fiber. The critical angle is defined as the angle of incidence above 
which TIR occurs. When the incident light is totally reflected internally, a small portion 
of light penetrates the rarer medium, i.e., the cladding (n2). This electromagnetic field is 
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called evanescent wave, and has an intensity that decays exponentially with distance, 
starting at the interface and extending into the medium of lower refractive index. The 
evanescent wave can interact with molecules in the penetration depth, thus producing a 
net flow of energy across the reflecting surface in the medium with lower refractive index 
to maintain the evanescent field. This transfer of energy leads to attenuation in 
reflectance called attenuated total reflection (ATR). This phenomenon has been utilized 
to develop ATP absorption sensors.114  
Optical fiber biosensors have been used in combination with different types of 
spectroscopic techniques such as absorption, fluorescence, phosphorescence, and surface 
plasmon resonance (SPR). Fiber optic bisosensors based on absorbance may consist of 
the biological component immobilized close to the optical fiber or directly on its surface. 
The biological component interaction with the analyte results in a change in the 
absorbance which is related to the concentration of analyte. Light is directed to the optic 
fiber tip where the biological element is immobilized and the resulting radiation is 
directed back to the detector by the fiber. Several fiber optic biosensors based on 
absorbance measurements have been developed for use in medical applications115, 116 and 
molecular recognition.117 
Fluorescence-based fiber optic systems consist of a biological component that is 
intrinsically fluorescent or is labeled with a fluorescent molecule. In such biosensors the 
biological components may also be enzymes that catalyze reactions leading to the 
production or consumption of fluorescent species. For example, dehydrogenases that 
catalyze nicotinamide adenine dinucleotide (NAD)-dependent reactions have been used 
for the development of several fiber optic biosensors; these reactions produce NADH or
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Figure 1.10 Total internal reflection in optical fiber. 
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NADPH, which can be detected by their fluorescence at ex = 350 nm, em = 450 nm.118, 
119 In another example a fiber optic biosensor for glucose based on fluorescence 
resonance energy transfer was developed.120 In this system two optical fibers were 
inserted in a hollow fiber, which was filled with assay solution containing fluorescein 
isothiocyanate (FITC)-Dextran as the donor and tetramethylrhodamine isothiocyanate 
(TRITC) labeled ConA (TRITC-ConA) as the acceptor (quencher). In the absence of 
glucose the donor and the acceptor are significantly close together for the fluorescein 
signal to be quenched by rhodamine. However, in the presence of glucose the FITC-
Dextran is separated from the TRITC-ConA and the fluorescein signal increases in a 
dose-dependent manner. Hence, this system enables the monitoring of glucose 
concentrations as a function of changes in fluorescence.  
 A fluorescent fiber optic immunosensor involves the immobilization of an 
antibody or antigen on the distal end of the fiber. The incident light introduced at the 
proximal end of the fiber travels through the fiber via TIR causing excitation of the 
fluorophore attached to either the antigen or a secondary antibody.121  A variety of fiber 
optic based immunosensors for the detection of pesticides have been developed. In an 
example, a hapten, a derivative of triazine (pesticide), was immobilized on the end of a 
hard clad silica fiber.122 The fiber was then incubated with a fluorescently labeled 
antibody and a sample containing unknown amounts of triazine. This competitive 
immunoassay is based on measurements of the changes in fluorescence signal to 
determine the amount of triazine present in a sample.122 
Immobilization of enzyme based sol-gels on the fiber is another technique for 
developing fluorescent fiber optic sensors. Doong and coworkers developed a fiber optic 
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fluorescent biosensor for acetylcholine.123 In this approach acetylcholinesterase was 
immobilized in a sol-gel on the distal end of an optical fiber. The acetic acid formed as a 
result of the enzymatic reaction between acetylcholinesterase and acetylcholine causes a 
change in the fluorescence intensity of the pH-sensitive fluorescent dye FITC-Dextran. 
This system was used for the detection of Paraoxon, an organophosphorous pesticide, as 
Paraoxon inhibits acetylcholinesterase, thus increasing fluorescence. 
 Surface plasmon resonance (SPR) is a direct optical detection method. SPR is 
based on TIR, wherein the TIR interface is coated with a thin layer of conducting metal. 
Polarized light penetrates the metal layer and excites electromagnetic surface plasmon 
waves propagating within the conductor surface, which is in contact with the low 
refractive index medium. SPR has successfully been employed in the development of 
immunosensors for simple and rapid assay of several analytes. Fiber optic SPR sensors 
are small and suitable for use at remote sites. Several fiber optic SPR sensors have been 
reported.124-127 Slavik et al. described the fabrication of a single-mode fiber optic SPR 
device.128 The sensing element was created by coating the fiber with a 65-nm layer of 
gold followed by a 19-nm layer of tantalum pentoxide. The sensor was used for detecting 
IgG concentrations in nanomolar ranges. Further, in continuation of the above mentioned 
work, a double layer of anti-Staphylococcal enterotoxin B (SEB) antibody crosslinked by 
glutaraldehyde was immobilized on the sensor surface for the detection of SEB.129 A 
fiber optic SPR immunosensor known as BIAcore probe, which enables dipstick-type 
sampling, has been launched by the Swedish company BIAcore.130 
 One drawback of fiber optic sensors is the variation in response and signal 
intensity from fiber to fiber.113 Immobilization of biological recognition elements on 
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optical fibers has led to increases in selectivity, sensitivity, and in some cases 
reversibility.112 Fiber optic sensors have several advantages, in that they are usually 
compact and light weight, minimally invasive, and they are not affected by 
electromagnetic interferences from static electricity, strong magnetic fields, or surface 
potentials.112, 113  
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STATEMENT OF RESEARCH 
 
The goal of this work was to first create designer proteins with enhanced stability and 
activity by global incorporation of unnatural amino acids into the structure of GBP and 
truncated fragments of GBP. Also, modified antibodies were created by photolabeling the 
unconventional region of the antibody variable region with a fluorophore conjugated 
nucleotide probe. Secondly, the goal of this work was to develop fiber optic glucose 
biosensor by using GBP and the unnatural amino acid incorporated proteins covalently 
attached within a hydrogel and immobilized on a tip of an optical fiber. Also, modified 
antibodies can be utilized to develop universal biosensing system for various 
biomolecules since modifying antibodies in the unconventional region does not affect 
antigen binding. The overall hypotheses for this work have ben formulated below:  
 Thermal stability and glucose binding activity of GBP can be altered by global 
incorporation of unnatural amino acids and these unnatural proteins can be 
utilized for the development of biosensor for continuous glucose monitoring in 
physiologically relevant glucose concentrations.  
 The newly created glucose-recognition proteins can be incorporated into hydrogel 
polymer networks, placed at the tip of a fiber optic system and employed in the 
continuous monitoring of glucose in blood. 
 Antibody based biosensing systems/assays can be developed by labeling the 
unconventional nucleoside binding site with an environment sensitive fluorophore 
conjugated to a nucleotide/nucleoside probe, and correlating the changes in 
fluorescence intensity in the presence of the analyte. 
48 
 
GBP has been extensively studied and utilized for developing glucose sensors. 
However, to the best of our knowledge, no thermally stable GBP or its fragments have 
been created by global incorporation of unnatural amino acids. Also no glucose biosensor 
has been developed with unnatural GBP able to detect glucose in physiologically relevant 
mM ranges. Moreover no fluorescent antibodies have been developed by photolabeling 
the unconventional region in the variable region of antibodies. It was our belief that 
global incorporation of unnatural amino acids in GBP would alter the stability and 
activity of GBP and further modifying the antibodies via fluorophore conjugated 
nucleotides we can develop universal biosensing system for a variety of biomolecules.  
 Chapter Two describes the universal strategy for designing antibody based 
sensing molecules by labeling an inherent nucleoside binding site. Here as a proof 
of concept Interleukin 6 was chosen as an analyte to be detected with our 
modified antibody-based biosensing system. 
 Chapter Three describes the development of a biosensing system for monitoring 
bone loss. Herein, we utilize the biosensing system based on fluorophore 
modified monoclonal antibody for the detection of Osteonectin, which is a bone 
biomarker. 
 Chapter Four describes the method of global incorporation of unnatural amino 
acids in GBP and its truncated fragments. It also details the analysis of structure, 
stability and activity of the unnatural proteins.  
 Chapter Five describes the development of fiber optic based biosensor for 
glucose, wherein, GBP and unnatural amino acid incorporated GBP and GBP 
fragments are immobilized in a hydrogel. 
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CHAPTER TWO 
 
 
UNIVERSAL STRATEGY FOR DESIGNING ANTIBODY BASED SENSING 
MOLECULES BY LABELING AN INHERENT NUCLEOSIDE BINDING SITE 
 
The quest for specific and sensitive sensing methods for target molecules is an on-
going challenge. While the utility of biosensors has been proven, their development has 
been limited to the availability of natural or artificial receptors that recognize the target 
molecule.  Herein, a universal approach is demonstrated for the design of antibody based 
sensing molecules that overcome this limitation. In particular, the antibody is modified by 
covalently attaching a nucleoside probe containing an environment-sensitive fluorophore 
to the inherent non-canonical nucleoside-binding site of the antibody. The non-canonical 
nucleoside binding site resides between the light and the heavy chains of the variable 
domain of antibodies, and tethering nucleoside probes to this site does not affect antigen 
binding.131, 132  The binding of the antigen to the antibody causes a change in the 
microenvironment of the nucleoside-binding site that is manifested by an alteration in the 
fluorescence properties of the fluorophore in a manner that is related to the concentration 
of antigen present in the sample. This relationship constitutes the basis for the 
development of the antibody based assays and biosensing systems.  
Antibodies have found wide applicability in a range of immunoassay127, 133, 134 and 
biosensor135-137 formats. Fluorescent antibodies with a potential to be used as biosensors 
have been developed, wherein, a fluorescent stilbene derivative is bound to the antigen 
binding site138-141. Besides the antigen binding site, an inherent non-canonical site is 
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present in the variable domain of immunoglobulin (Ig) formed by invariant residues of 
both light and heavy chains of Ig, which binds purine containing nucleoside photoaffinity 
probes with high affinity.1 The purine ring is held via base-stacking interactions within 
the non-canonical site, while the ribose ring is exposed to the surface of the molecule 
allowing a number of reporter moieties to be tethered to the antibody.131, 132 Docking to 
this unconventional site does not interfere with antigen binding.2 Amino acids in the non-
canonical site that make contact with the nucleotide moiety include Tyr from the light 
chain, as well as Asp and Trp from the heavy chain.1 To demonstrate the prevalence of 
these amino acids within the non-canonical site, the sequences of a series of IgGs were 
aligned. The sequences of 740 Fab antibody fragments were obtained from the Protein 
Data Bank by searching with the keyword “Fab antibody” (search conducted on 20th 
October 2010).The sequences were then sorted by their release date. The most recently 
released 100 Fab sequences thus obtained with both the heavy and the light chains were 
aligned using T-Coffee software.142 The sequence alignment confirms the presence of the 
three invariant amino acids in the light and heavy chains of antibodies. Herein, we 
describe a reagentless (i.e., no need for use/addition of reagents) biosensing system based 
on an antibody labeled with a fluorescent nucleotide probe (Figure 2.1). This strategy is 
universal as it can be used for the detection of any given molecule provided the 
availability of a specific antibody toward this target molecule.  
To demonstrate the feasibility of this approach, we utilized an anti-interleukin 6 
(IL-6) monoclonal antibody that binds selectively to IL-6. IL-6 is a multifunctional 
cytokine consisting of 185 amino acids secreted by T cells and macrophages.143 IL-6 
promotes inflammatory events through activation of T cells, differentiation of B cells, 
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FIGURE 2.1 Schematic showing the strategy for development of biosensing system 
based on fluorophore labeled monoclonal antibody 
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and the induction of acute phase reactants by hepatocytes.144, 145 In addition, IL-6 plays a 
protective role during disease, acting both as a pro- and an anti-inflammatory cytokine.146 
Elevated concentrations of IL-6 in body fluids have been reported in various disease 
states such as cardiac myxomas and cardiovascular diseases147-149 and is employed as a 
general marker of inflammation.150 
 
 
EXPERIMENTAL PROCEDURES 
 
Materials 
Mouse anti-IL-6 monoclonal antibody and recombinant Human IL-6 were 
purchased from USBiological (Massachusetts, MA). Nucleotide probes 8-N3ATP and 2-
N3ATP were obtained from Affinity Labeling Technologies (ALT) Corporation 
(Lexington, KY). Alexa Fluor 594 cadaverine was obtained from Invitrogen (Eugene, 
OR). The Bradford protein assay kit was obtained from Bio-Rad laboratories (Hercules, 
CA). Carry Eclipse Spectrophotometer (Milpitas, CA) was used for fluorescence 
measurements. 
 
Methods 
Selecting the photoaffinity probe 
Two radioactive nucleotide probes, [γ-32P]8-N3ATP and [γ-
32P]2-N3ATP were 
evaluated for their reactivity with mouse anti-interleukin 6 monoclonal antibody. For the 
labeling procedure 8 µg of antibody was incubated with 300 µM of each probe in two 
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different tubes in a final volume of 62 μL on ice for 10 min. After 10 min incubation, the 
two tubes were photolyzed with a hand-held UV lamp at 254 nm for 2 min, while the 
reaction mixture was agitated in-between to prevent local heating. The reaction was 
quenched by adding protein solubilizing mixture (10% SDS, 3.6 M urea, 162 mM DTT, 
0.0025% Pyronin Y, 20 mM Tris, pH 8.0) and heating it in a water bath for 5 min. The 
reaction products were then analyzed by SDS PAGE. 32P incorporation was detected by 
autoradiography.  
 
Saturation of labeling 
An amount of 2 μg of mouse anti-interleukin 6 monoclonal antibody was 
incubated with increasing concentrations of [γ-32P]2-N3ATP for 20 min on ice and 
photolyzed with a hand-held lamp at 254 nm for 75 s. The reaction was quenched by 
adding 5 μL of 0.25 mg/mL cysteine and analyzed by SDS/PAGE and autoradiography.  
 
Conjugation of 2-N3ATP to Alexa Fluor 594 cadaverine 
The conjugation of 2-N3ATP to the fluorophore was done at Affinity Labeling 
Technologies. A 1:1 ratio of 2-N3ATP and Alexa Fluor 594 cadaverine (Invitrogen) was 
added to 0.1 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 5 mM sulfo-N-
hydroxysulfosuccinimide and allowed to react at room temperature for 2 h. The conjugate 
was then purified using a diethylaminoethyl cellulose column and an elution gradient of 0 
-300 mM triethylammonium carbonate. 
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Determination of KD of the monoclonal antibody for 2-N3ATP-fluorophore 
Competitive labeling of the anti-interleukin 6 (IL-6) monoclonal antibody with 2-
N3ATP [γ 
32P] and 2-N3ATP-fluorophore was done. 2-N3ATP [γ 
32P] (30 µM) and 2 µg 
of the antibody was added to each 10 µM, 20 µM, 40 µM, 60 µM, 80 µM, 100 µM and 
120 µM of 2-N3ATP-fluorophore tube and incubated for on ice 20 min. The tubes were 
then photolyzed for 75 s. The reaction was quenched by adding 5 μL of 0.25 mg/mL 
cysteine and analyzed by SDS/PAGE and autoradiography. The apparent KD was 
determined using GraphPad Prism 5 software. 
 
Conjugation of the antibody to the 2-N3ATP-fluorophore  
For the conjugation of 2-N3ATP-Alexa Fluor 594 cadaverine to the antibody, 4 μg 
of the antibody was incubated with 30 μM 2-N3ATP labeled fluorophore in a final 
volume of 50 μL for 20 min, on ice and in the dark. The reaction was photolyzed with a 
hand-held UV lamp at 254 nm for 4 min. To quench the photolytic reaction, cysteine (10 
μL of 1mg/ml) was added. The unbound fluorophore was separated from the antibody 
bound fluorophore by dialyzing against six changes of 10 mM phosphate buffer, pH 7.0 
over 24h. 
 
Fluorescence studies of the interaction of the labeled antibody with IL-6 
The effect of IL-6 binding on the fluorescence signal of the label attached to the 
non-canonical site of the IL-6 antibody was studied by incubating 4 μg/mL of the labeled 
antibody with different concentrations of IL-6 for 30 min at room temperature in the 
dark. The sample solutions were prepared using 10 mM phosphate buffer, pH 7.0. The 
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fluorescence intensity of the samples (total volume 200 µL) was measured on a Cary 
Eclipse Spectrofluorometer.  
 
 
RESULTS AND DISCUSSION 
 
Nucleotide probes conjugated with a fluorophore can be docked to the non-
canonical nucleoside binding site of the antibody without interfering with binding of 
antigen to the canonical antigen-binding site. The mouse anti-human IL-6 monoclonal 
antibody was labeled with two photoreactive probes, [γ-32P]-2-N3ATP (Figure 2.2a) and 
[γ-32P]-8-N3ATP (Figure 2.2b) to test their reactivity toward the antibody. Both the light 
and heavy chains were labeled with the radioactive probe indicating that the nucleoside 
binding site is composed of amino acids located on both chains (Figure 2.3a). It was also 
determined that [γ-32P]-2-N3ATP labels the antibody better than [γ-
32P]-8-N3ATP (Figure 
2.3b). Further, to optimize the efficiency of labeling the antibody with the photoreactive 
probe, the concentration of the probe required to label the antibody was determined by 
incubating anti-IL-6 monoclonal antibody with increasing concentrations of [γ-32P]-2-
N3ATP followed by exposure to UV light to activate the photolabel (Figure 2.4). The 
concentration of probe selected to label the antibody in all subsequent experiments was 
~25 µM, as this is relatively low concentration and generates a good signal.  
After proving that [γ-32P]-2-N3ATP labeled the antibody successfully, a 
fluorescent, rather than radiolabeled derivative of 2-N3ATP was synthesized. In that 
regard, Alexa Fluor 594 cadaverine was selected for coupling to 2-N3ATP.  This 
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Figure 2.2 Structures of nucleotide probes utilized for photolabeling of antibody. (a) 
[γ32P] 2-N3ATP (b) [γ-
32P] 8-N3ATP 
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Figure 2.3 Antibody labeled with radioactive nucleotide probes. (a) autoradiogram of the 
antibody labeled with the photoreactive probes [γ-32P] 2-N3ATP (A) and [γ-
32P] 8-N3ATP 
(B). Lanes 1, 4; 2, 5; and 3, 6 correspond to the use of 0.6 μg, 1.3 μg and 1.9 μg of 
labeled antibody, respectively. (b) Normalized data obtained from the autoradiogram of 
antibody labeled with the photoreactive probes. 
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Figure 2.4 Saturation of photolabeling of antibody with [γ-32P] 2-N3ATP. 
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fluorophore has long excitation and emission wavelengths (590 nm/617 nm), thus 
circumventing interferences from common fluorescent compounds present in biological 
samples. The amine functional group of Alexa Fluor 594 cadaverine was utilized for 
conjugation to 2-N3ATP, since it was observed that 2-N3ATP labels the antibody with a 
greater efficiency than the 8-N3ATP vide supra. The apparent KD for 2-N3ATP-Alexa 
Fluor 594 (Figure 2.5) cadaverine to the non-canonical site was determined to be ~17 
µM. The fluorescently labeled nucleotide was further conjugated to the mouse anti-
human IL-6 monoclonal antibody at the non-canonical site upon exposure to UV light. 
The effect of antigen (IL-6) binding on the fluorescence signal of the 2-N3ATP-
Alexa Fluor 594 (Figure 2.6a) labeled antibody was evaluated. The apparent KD for IL-6 
to the fluorophore labeled antibody was determined to be ~2.4 x 10-8 M. It was observed 
that binding of IL-6 to the antibody resulted in an increase of the fluorescence intensity of 
the fluorophore with increasing concentration of antigen (Figure 2.6b). The experiments 
suggest that binding of IL-6 to the antigen binding site induces a change in the 
conformation of the non-canonical site causing a change in the microenvironment 
surrounding the fluorophore, which is manifested by a change in the fluorescence signal. 
Because the site in the antibody where the fluorescent probe is bound is adjacent to the 
antigen-binding site in the variable region of the antibody, there is an allosteric effect that 
upon antigen binding alters the fluorescence signal of the fluorophore.  
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Figure 2.5 Competitive labeling of anti-interleukin 6 (IL-6) monoclonal antibody with 2-N3ATP 
-Alexa Fluor 594 cadaverine and 2-N3ATP [γ 
32P].   
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Figure 2.6 Structure of fluorescent nucleotide probe and the effect of Il-6 on the 
fluorescence intensity of the probe. (a) 2-N3ATP-Alexa Fluor 594 cadaverine (b) Dose-
response curve for IL-6. Data are the average of ± one standard deviation (n=3). Relative 
standard deviations at all concentrations are less than 10%. 
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CONCLUSIONS 
 
Herein we have developed a universal method for the design of biosensors.  We 
demonstrated that a fluorophore-modified nucleotide probe can bind to the non-canonical 
site of the antibody without affecting antigen binding. Additionally, we have shown that 
binding of the antigen to the antibody alters the fluorescence intensity of the fluorophore-
modified nucleotide probe in an allosteric fashion. The change in fluorescence intensity 
of the label can be correlated to the concentration of IL-6 in the sample. Because of the 
widespread nature of this non-canonical site among IgGs, and availability of antibodies 
for practically any molecule of interest, this versatile biosensing approach should find 
wide applicability in a variety of fields where detection of antigen-antibody interactions 
is important.  Among those, we can envision their use in sensing in a variety of samples, 
imaging, localization of target molecules in cells, etc. 
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CHAPTER THREE 
 
BIOSENSING SYSTEM BASED ON MODIFIED ANTIBODY FOR 
MONITORING BONE LOSS  
 
INTRODUCTION 
Bone undergoes mass changes throughout life, also referred to as bone 
remodeling. Bone remodeling involves cycles of bone deposition by osteoblasts and bone 
resorption by osteoclasts.151 Bone remodeling allows for the renewal of bones in 
vertebrates. Bone is continuously remodeled in response to mechanical and physiological 
stress.152 Bone mass is maintained by a balance between the rates of bone deposition and 
bone resorption.151 However, when the rate of bone resorption is faster than the rate of 
bone deposition it leads to a disorder called osteoporosis.151 Osteopenia is another bone 
disorder where bone mass is less than average. It is sometimes also referred to as onset of 
osteoporosis. Besides these health conditions, bone mass loss is also reported in humans 
after prolonged space flights and weightlessness or microgravity.153, 154 Although the 
mechanism of microgravity induced bone loss is not fully known, it has been attributed to 
a decrease in osteoblast function without a significant change in bone resorption.154 
Several ground based studies on microgravity induced bone loss have been performed 
using various models. These studies suggest that bone loss may occur because of 
inhibition of osteoblast differentiation from human mesenchymal stem cells due to a 
failure in cellular expression of osteonectin.  
Osteonectin is a 32,000 kDa glycoprotein occurring in the noncollagenous matrix 
of bone, extracellular matrices and some body compartments including blood platelets.155, 
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156 Hence, two forms of ON are known, a bone derived form and a platelet derived form. 
Osteonectin is a major constituent of basement membrane matrix of many embryonic and 
adult tissues.157 Osteonectin contains structural domains including an acidic domain, 
which is rich in aspartic and glutamic acid, a NH2-terminal domain, a cysteine rich 
domain with potential glycosylation sites, an alpha helical domain, and two calcium 
binding motifs.157, 158 ON binds to type I collagen and hydroxyapatite and, consequently, 
plays a key role in initiating mineral deposition and linking mineral to the matrix.159 
Osteonectin deficient mice have shown decreased bone mineral density and a decreased 
function of osteoblasts and osteoclasts resulting in osteopenia.151 Several animal models 
of bone fragility show a decreased expression of osteonectin. Further, osteonectin has 
also been determined as a salivary biomarker of alveolar bone loss.160, 161 Herein, we 
present an antibody based biosensing system for osteonectin that could find application in 
the prevention and treatment of bone loss for healthier life. Our biosensing system is 
based on the previously developed concept of conjugating a fluorophore labeled 
nucleotide at the non-canonical site of an antibody in which change in the conformation 
induced by the binding of antigen at the antigen binding site causes a change in 
fluorescence intensity. Specifically, we used a monoclonal antibody against osteonectin, 
which was labeled with 2-N3ATP conjugated to Alexa Fluor 594 cadaverine. The 
intensity of fluorescence of the label was found to increase with increasing osteonectin 
concentration in the sample. 
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EXPERIMENTAL PROCEDURES 
 
Materials  
Anti-human osteonectin/SPARC monoclonal antibody was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Human recombinant osteonectin was purchased 
from ALPCO Diagnostic (Salem, NH). Nucleotide probes 8-N3ATP and 2-N3ATP were 
obtained from Affinity Labeling Technologies (ALT) Corporation (Lexington, KY). 
Alexa Fluor 594 cadaverine was obtained from Invitrogen (Eugene, OR). The Bradford 
protein assay kit was obtained from Bio-Rad laboratories (Hercules, CA). Carry Eclipse 
Spectrophotometer (Milpitas, CA) was used for fluorescence measurements 
 
Methods 
 
Selecting the photoaffinity probe 
   Two radioactive nucleotide probes, [γ-32P]8-N3ATP and [γ-
32P]2-N3ATP were 
evaluated for their reactivity with mouse anti-osteonectin monoclonal antibody. For the 
labeling procedure 8 µg of antibody was incubated with 358 µM of each probe in two 
different tubes in a final volume of 58 μL on ice for 10 min. After 10 min incubation, the 
two tubes were exposed to UV light with a hand-held UV lamp at 254 nm for 75 s, while 
the reaction mixture was agitated in-between to prevent local heating. The reaction was 
quenched by adding a protein solubilizing mixture (10% SDS, 3.6 M urea, 162 mM DTT, 
0.0025% Pyronin Y, 20 mM Tris, pH 8.0) and heating it in a water bath for 5 min. The 
reaction products were then analyzed by SDS PAGE. 32P incorporation was detected by 
autoradiography.  
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Conjugation of 2-N3ATP to Alexa Fluor 594 cadaverine 
The conjugation of 2-N3ATP to the fluorophore was performed at Affinity 
Labeling Technologies. A 1:1 ratio of 2-N3ATP and Alexa Fluor 594 cadaverine was 
added to 0.1 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 5 mM sulfo-N-
hydroxysulfosuccinimide and allowed to react at room temperature for 2 h. The conjugate 
was then purified using a diethylaminoethyl cellulose column and an elution gradient of 0 
-300 mM triethylammonium carbonate. 
 
Conjugation of the antibody to the 2-N3ATP-fluorophore  
For the conjugation of 2-N3ATP-Alexa Fluor 594 cadaverine to the antibody, 0.2 
mg/mL of the antibody was incubated with 90 μM 2-N3ATP labeled fluorophore in a 
final volume of 100 μl for 20 min, over ice and in dark, in two flat bottom eppendorf 
tubes. The reaction mixture was exposed to UV light with a hand-held UV lamp at 254 
nm for 2 min. To quench the photolytic reaction, cysteine (12.5 μL of 1mg/mL) was 
added. The unbound fluorophore was separated from the antibody bound fluorophore by 
dialyzing against six changes of 10 mM phosphate buffer, pH 7.0 over 24h. The 
concentration of fluorophore-labeled antibody (ON antibody-2-N3ATP-Alexa Fluor 594 
cadaverine) was determined by Bradford assay. 
 
Calibration curve for osteonectin antibody-2-N3ATP-Alexa Fluor 594 cadaverine 
In order to generate calibration curves for the ON antibody-2-N3ATP-Alexa Fluor 
594 cadaverine serial dilutions were made of fluorophore-labeled antibody from a stock 
solution at concentration of 6.7 x 10-7 M with 10 mM phosphate buffer, pH 7.0. 
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Fluorescence measurements were performed in a microtiter plate with 100 μL samples. 
The samples were excited at 590 nm and the emission was measured at 617 nm. A 
volume of 100 μL of 10 mM phosphate buffer, pH 7.0, was used as blank. The 
fluorescence intensity of the samples was measured on a Cary Eclipse 
Spectrofluorometer.  
 
Association study 
A volume of 50 μL of 3 x 10-8 M fluorophore-labeled antibody and 50 μL of 
varying concentrations of osteonectin ranging from 1 x 10-7 M to 1 x 10-10 M were 
incubated in a microtiter plate for a time period ranging from 5 to 60 min at room 
temperature. The fluorescence of the samples in microtiter plate were measured upon 
excitation at 590 nm after every 5 min for 30 min and every 15 min from 30 to 60 min. A 
sample of 100 μL fluorophore-labeled antibody was used as a control and 10 mM 
phosphate buffer, at pH 7.0, was used as blank. 
  
Fluorescence studies of the interaction of the labeled antibody with osteonectin 
The effect of ON binding on the fluorescence signal of the label attached to the 
non-canonical site of the ON antibody was studied by incubating 4 μg/mL of the labeled 
antibody with different concentrations of ON for 30 min at room temperature in the dark. 
The sample solutions were prepared by mixing 100 µL of antibody solution and 100 µL 
of ON solution. The solutions were made in 10 mM phosphate buffer, pH 7.0. The 
fluorescence intensity of the samples (total volume 200 µL) was measured on a Cary 
Eclipse Spectrofluorometer.  
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Selectivity study 
In order to determine whether the monoclonal antibody based sensor is selective 
for osteonectin, 4 μg/mL fluorophore labeled antibody was incubated with different 
concentrations of osteonectin and inteleukin-6 (IL6) separately in a total volume of 200 
μL in a microtiter plate for 25 min in dark at room temperature. The fluorescence of the 
samples was measured upon excitation at 590 nm. A sample of 100 μL fluorophore-
labeled antibody was used as a control and 10 mM phosphate buffer, pH 7.0, was used as 
blank. 
 
 
RESULTS AND DISCUSSION 
 
An anti-osteonectin monoclonal antibody was labeled with two radioactive 
nucleotide probes, [γ-32P]-2-N3ATP and [γ-
32P]-8-N3ATP to determine the reactivity of 
the probes against the osteonectin antibody. The photolabeld osteonectin antibody was 
analyzed via SDS PAGE analysis to determine which nucleotide probe labels the 
antibody better. The determination of 32P incorporation via autoradiography indicates that 
both the light and heavy chains of osteonectin antibody are labeled with the radioactive 
probe. Hence, the nucleotide binding site resides within the light and heavy chain of 
antibody. Autoradiogram data (Figure 3.1) also show that [γ-32P]-2-N3ATP labels the 
antibody better than [γ-32P]-8-N3ATP. Therefore, for further experiments the osteonectin 
antibody was labeled with the fluorescent derivative of 2-N3ATP. 
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Figure 3.1 Data obtained from autoradiograph of monoclonal antibody against 
osteonectin with [γ-32P]8-N3ATP and [γ-
32P]2-N3ATP. HC= Heavy Chain, LC=Light 
Chain. 
 
 
 
 
 
 
 
70 
 
In our biosensing system, we utilized the non-canonical nucleotide binding site to 
dock a fluorescent reporter molecule covalently attached to 2-N3ATP. We utilized Alexa 
Fluor 594 cadaverine as the fluorescent reporter molecule, because it has long excitation 
and emission wavelengths (590 nm/617 nm), thus circumventing interferences from 
common fluorescent compounds present in biological samples. The amine functional 
group of Alexa Fluor 594 cadaverine was utilized for conjugation to 2-N3ATP. Alexa 
Fluor 594 cadaverine labeled 2-N3ATP was further conjugated to the osteonectin 
monoclonal antibody at the non-canonical site upon exposure to UV light. Haley and 
coworkers have previously determined via computer modeling that the nucleoside base is 
sandwiched between the rings of an invariant Trp in the heavy chain and Pro in the light 
chain forming the non-canonical binding site.131 The azido group of the purine ring on the 
other hand forms a covalent bond with the amino acids in the light chain of antibody 
upon irradiation with UV light131. The unbound nucleotide fluorophore conjugate to the 
ON antibody was separated from the fluorophore-bound antibody by dialysis, and the 
protein concentration of the fluorophore-labeled antibody was determined by Bradford 
assay. 
 The amount of fluorophore-labeled antibody required for further experiments was 
determined by generating calibration curves that relate the amount of fluorescent signal to 
the different concentrations of the fluorescent antibody (Figure 3.2). The concentration of 
fluorescent antibody selected for further experiments was 1 X 10-8 M as this was a 
relatively low concentration that generates a good detectable signal. 
 To determine the amount of time required to obtain the maximum possible change 
in the signal upon incubating the fluorescent osteonectin antibody with osteonectin, an 
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Figure 3.2 Calibration curve for 2-N3ATP-Alexa Fluor 594 labeled antibody against 
osteonectin. Data are the average of ± one standard deviation (n=3). Relative standard 
deviations at all concentrations are less than 10%. 
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Figure 3.3 Association curve for 2-N3ATP-Alexa Fluor 594 labeled antibody against 
osteonectin with osteonectin. Data are the average of ± one standard deviation (n=3). 
Relative standard deviations at all concentrations are less than 10%. 
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association study was performed. Figure 3.3 shows the association curve for fluorescent 
osteonectin antibody with osteonectin. A maximum increase of fluorescence intensity 
was obtained after 30 min incubation of fluorescent antibody and antigen. However, a 
distinguishable increase of fluorescence intensity was observed after 25 min incubation 
of antibody and antigen. The time study shows a lag phase over the first 15 min of 
incubation of the analyte (antigen) with the fluorophore labeled antibody. This lag phase 
can be because of the time required for the diffusion of the analyte in the binding site of 
the antibody or the conformation change in the binding site in the presence of the analyte. 
Therefore, for all subsequent experiments an incubation time of 25 min was used. 
 A dose-response curve (Figure 3.4) was generated to evaluate the effect of antigen 
(osteonectin) binding on the fluorescence signal of the 2-N3ATP-Alexa Fluor 594 labeled 
antibody. An increase in the fluorescence signal was observed with increasing 
concentration of antigen. The change in the fluorescence is attributed to the change in the 
microenvironment surrounding the fluorophore induced by the change in the 
conformation of the non-canonical site to which the fluorophore is bound. As previously 
described by Haley and coworkers this non-canonical site resides adjacent to the antigen 
binding site in the variable region of the antibody. Therefore, there is an allosteric effect 
that upon antigen binding alters the fluorescence signal of the fluorophore. 
 To evaluate the selectivity of our biosensing system for osteonectin, selectivity 
studies were done by incubating the fluorophore-labeled osteonectin antibody with 
varying concentrations of osteonectin and IL6 for 25 min and the change in fluorescence 
intensity was measured. Figure 3.5 shows an increase in the fluorescence intensity of 
osteonectin antibody with increasing concentrations of osteonectin. However, no change 
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Figure 3.4 Dose-response curve for osteonectin. Data are the average of ± one standard 
deviation (n=3). Relative standard deviations at all concentrations are less than 10%. 
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Figure 3.5 Selectivity studies for 2-N3ATP-Alexa Fluor 594 labeled antibody against 
osteonectin with osteonectin and IL6. Data are the average of ± one standard deviation 
(n=3). Relative standard deviations at all concentrations are less than 10%. 
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in the fluorescence intensity is observed for osteonectin antibody with increasing 
concentrations of IL6. This confirms that fluorophore-labeled osteonectin antibody binds  
specifically to osteonectin and hence, the biosensing system is very specific for the 
antigen. 
 
 
CONCLUSIONS 
 
 In conclusion we have demonstrated the use of our previously developed 
universal biosensing system for the detection of osteonectin based on labeling the non-
canonical nucleoside binding site of an anti-osteonectin antibody. We have also 
demonstrated that our biosensing system based on fluorescently labeled antibody is very 
selective for the antigen. Our biosensing system will help in the clinical analysis of 
osteonectin. Also this type of biosensing system can be extended to different kinds of 
analytes of interest. 
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CHAPTER FOUR 
 
Designer Glucose Recognition Proteins via Global Incorporation of Unnatural 
Amino Acids 
 
INTRODUCTION 
A key advancement in biotechnology has been the ability to prepare designer 
proteins with a wide spectrum of chemical and physical properties. The properties of 
these proteins have been tailored, thus altering their function and stability, by employing 
a variety of chemical and genetic methods including the incorporation of unnatural amino 
acids into the protein structure162-166. Rather recently, it has been reported that the 
incorporation of unnatural amino acids allows to tune the properties and thermal stability 
of proteins.72, 167 Several fluorinated non-natural amino acids such as fluorovaline,168 
fluoroleucine,167-169 fluoroisoleucine,170 fluorophenylalanine171 and fluoroproline172 have 
shown to enhance thermal stability and resistance to chemical denaturation. Since 
fluorine has similar Van der Walls radii as hydrogen, it can be replaced in amino acids 
with minimal steric perturbation of the protein.173 Fluorine in high electronegative and 
hydrophobic amino acids confers distinct properties in proteins. Thus, adopting such a 
strategy could endow proteins with improved properties, increased temperature stability, 
increased shelf-lives, a decrease in refrigeration storing needs, and easier 
packaging/transport of these reagents.  In addition, it would allow for their use at RT and, 
potentially, in extreme environments. 
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GBP has been proposed as a recognition element in biosensors for the detection of 
glucose in a wide variety of fields, including in the management of diabetics.174, 175 GBP 
is a 33 kDa periplasmic binding protein39 with two similarly folded globular domains 
connected via three protein segments.10 The sugar-binding site is located within a cleft 
between the two domains of the protein. Upon glucose binding, a conformational change 
in the protein at the hinge region occurs. In the open form of GBP (in the absence of 
glucose) the two domains are far apart and the cleft is exposed to the solvent, while in the 
closed form the glucose is engulfed within the cleft.10 Construction of GBP-based 
fluorescent biosensors by covalently coupling organic chemical fluorophores to various 
amino acids introduced in the protein via mutagenesis, in or around the glucose binding 
pocket has been reported by us and others.10, 176, 177 Although these chemically-modified 
GBPs demonstrated sensitive and selective response to glucose, the need for highly stable 
sensors for long-term detection of glucose in hypoglycemic, normal and hyperglycemic 
ranges continues to be a challenge. 
Herein, we demonstrate the production of unnatural glucose recognition proteins 
(GRPs) by global incorporation of the unnatural amino acids 5-fluorotryptophan (FW) 
(Figure 4.1 a) and  5,5,5-trifluoroleucine (FL) (Figure 4.1b) within the structure of a 
genetically engineered GBP, GBP152, of E.coli and its truncated fragments (GRP1 and 
GRP2).42 In our work we replaced the natural leucines and tryptophans in GBP152 and 
its truncated fragments with FL and FW, and studied their structure, activity, and 
stability. Far-UV circular dichroism (CD) of GRPs-FW/FL revealed change in the 
secondary structure compared to GBP152, indicating that the incorporation of unnatural 
amino acids alter the secondary structure of proteins. Unnatural GRPs could still bind to  
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Figure 4.1 Chemical structures of unnatural amino acids incorporated in glucose 
recognition protein (a) 5-fluorotryptophan (b) 5,5,5-trifluorotryptophan 
 
 
 
 
 
a b 
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glucose; however their binding constants are affected by incorporation of unnatural 
amino acids. In contrast, temperature-induced CD changes showed an increase in the 
thermal stability of almost all GRPs-FL/FW except GRP1,2-FW, whose thermal stability 
remains unaltered.  
 
EXPERIMENTAL PROCEDURES 
 
Materials 
M9 minimal salts was purchased from DifcoTM (Sparks,MD) Ampicillin sodium 
salt, anhydrous calcium chloride, magnesium sulfate, calcium chloride, thiamine, 5-
fluorotryptophan, and 5,5,5-trifluoroleucine were purchased from Sigma-Aldrich (St. 
Louis, MO). Imidazole was purchased from J.T. Baker, Inv. (Phillipsburg, NJ). 
Isopropyl-β-D-thiogalactoside (IPTG) was purchased from Gold Biotechnology, Inc. 
(Houstan, TX). The Bradford protein assay kit was purchased from Bio-Rad laboratories, 
Inc. (Hercules, CA). Sodium Dodecyl Sulfate (SDS) was purchased from Curtin 
Mathesin Scientific, Inc. (Houstan, TX). Nickel-NitriloTriAcetic acid (Ni-NTA) agarose 
was purchased from Qiagen (Valencia, CA). Tris glycine SDS Page gels and 7-
diethylamino-3-((((2-maleimidyl)ethyl-amino)carbonyl)coumarin (MDCC) and YM-10 
Microcon centrifugal devices were purchased from Invitrogen (Carlsbad, CA). D-
Glucose, anhydrous was purchased from Spectrum (New Brunswick, NJ).) HEPES was 
purchased from VWR International (Bridgeport, NJ). All solutions were prepared using 
deionized reverse osmosis (MILL-Q Water purification System, Millipore, Bedford, MA) 
water.  
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Apparatus 
Cell cultures were grown on an orbital shaker from Forma Scientific (Marrietta, 
OH) and a Beckman J2-MI centrifuge (Palo Alto, CA) was used for harvesting the cells. 
GRPs-FW/FL were obtained by lysing the cells with a 550 Sonic Dismembrator from 
Fisher Scientific. Fluorescence studies of  GRPs-FW/FL in solution were performed on 
Varian Cary Eclipse fluorescence Spectrophotometer. CD measurements were performed 
with a Jasco model J-810 spectropolarimeter (JASCO Ltd. UK).  
 
Methods 
Expression and purification of GRPs-FW/FL  
Plasmid pQE70 with the gene encoding GBP152 and GRP42, 178 and pLacI were 
co-transformed into the E.coli tryptophan auxotroph ATCC #27873 for expression of 
GRPs-FW. Plasmid pQE70 with GBP152 and GRP42, 178 were transformed into the E. coli 
leucine auxotroph HB101F΄ for expression of GRPs-FL. Protein expression was 
performed using the medium shift method165. A single freshly transformed colony was 
used to inoculate 5 mL of M9 media supplemented with 0.4% glucose, 1 mM MgSO4, 0.1 
mM CaCl2, 1 mM Thiamine, 0.1 volume of a solution containing 0.01% (w/v) each of 19 
amino acids (-Leu/ or -Trp), 40 µg/mL Leu/ or Trp and 100 µg/mL ampicillin. This 
culture was allowed to grow overnight at 37 0C, 250 rpm. 500 mL culture containing the 
same ingredients was inoculated with the overnight grown 5 mL culture. This culture was 
then grown till the optical density (OD600) was ~0.5- 0.6. The cells were then centrifuged 
at 10,000 rpm for 10 min, 25 0C, the supernatant was discarded and the cells were 
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resuspended in a 0.9% NaCl solution for washing, and this was repeated three times. The 
cells were then resuspended in 500 mL M9 minimal media which was supplemented with 
0.4% glucose, 1 mM MgSO4, 0.1 mM CaCl2, 1 mM Thiamine, 0.1 volume of a solution 
containing 0.01% (w/v) each of 19 amino acids (-Leu/ or -Trp), 100 µg/ml ampicillin, 
and grown at 37 0C for 30 min to further deplete leucine. 1 mM Isopropyl β-D-1-
thiogalactopyranoside, IPTG was then added with 0.1 mM of 5,5,5-fluoroleucine/ or 5-
fluorotryptophan to the culture and was grown overnight at 37 0C. The cells were 
harvested by centrifugation and the protein was purified using Ni-NTA resin. The 
purified protein was dialyzed against 3 changes of 10 mM Hepes, 0.2 mM CaCl2, pH 7.2.  
 
Mass Spectrometry 
SDS Page gel pieces of all three proteins with unnatural amino acids were 
digested with trypsin, and LC-ESI-MS-MS was performed using a ThermoFinnigan LTQ. 
Resulting MS-MS spectra were searched against proteins in the Swiss-Prot database 
using the mascot search engine (Matrix Science). The difference in mass of GBP152 and 
GRPs confirmed the incorporation of the unnatural amino acids. 
 
Circular Dichroism 
CD measurements were performed with a Jasco model J-810 spectropolarimeter 
with a 1 nm bandwidth using a 0.1 cm pathlength cuvette for the far UV scans. The 
concentration of proteins used for far UV scans and temperature scan were 0.10 mg/mL 
of GRP-FW, 0.29 mg/mL of GRP1-FW, 0.20 mg/mL of GRP2-FW, 0.17 mg/mL of 
GRP-FL, 0.18 mg/mL of GRP1-FL, and 0.29 mg/mL of GRP2-FL. The proteins were 
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dialyzed against a low salt buffer (5 mM phosphate) before CD measurements. The 
thermal stability of GGBP secondary structure was monitored by heating samples over 
the range 0 - 99 °C. The mean residue molar ellipticity at 222 nm was recorded at 0.2 °C 
intervals using a time constant of 8 s.  
 
Labeling GRPs-FL/FW with MDCC (N-[2-(1-maleimidyl(ethyl]-7-
(diethylamino)coumarin-3-carboxamide) 
The purified protein was incubated with dithiothreitol (DTT) to a final 
concentration of 2 mM at 4 0C for 2 h. Excess DTT was removed using YM-10 microcon 
centrifugal device. The protein was then reacted overnight with 10X MDCC, 4 0C and in 
dark. The unreacted MDCC and glucose from the protein was removed by dialyzing 
against six changes of 10 mM Hepes, 0.2 mM CaCl2, pH 8.0. 
 
Fluorescence study of GRP1-FW/FL and GRP2-FW/FL in solution 
The excitation and emission wavelengths of MDCC were 425 nm and 475 nm, 
respectively. The concentration of labeled proteins used in the fluorescence studies was 1 
X 10-7 M. The MDCC conjugates were incubated with various glucose concentrations for 
1 min. All measurements were done at RT in quartz cuvettes with sample volume of 200 
µL. 
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RESULTS AND DISCUSSION 
GBP has a total of 22 leucines and 5 tryptophans. None of the 22 leucines is 
involved in the formation of bonds with glucose, thus incorporating FL into GBP should 
not affect the glucose binding ability of the protein. However GRP1 (bigger truncated 
fragment)42 has 5 tryptophans and 21 leucines while GRP2 (smaller truncated fragment)42 
has 4 tryptophans and 19 leucines. However, one of all the tryptophans in GBP and its 
truncated fragments is located within the glucose binding pocket of GBP152.39 Hence, 
incorporation of FWs in the protein might affect the binding ability and/or stability of the 
protein. Also as previously mentioned fluoroleucines have shown to enhance the thermal 
stability of proteins. Therefore, we hypothesized that global incorporation of FL and FW 
in GBP152, GRP1 and GRP2 may result in changes in the structure and/or stability of the 
protein. 
In our work we globally incorporated FL/FW into GBP152, a H152C GBP mutant 
and its two fragments that contains a unique cysteine located in close proximity to the 
glucose binding site. For the global incorporation of unnatural tryptophans in the 
GBP152 and GRPs, the pQE70 vector with GBP152 or GRP1 or GRP2 was co-
transformed with plasmid placI in E. coli tryptophan auxotrophic strain. Plasmid pLacI 
was transformed in the cells to control the expression of protein. For global incorporation 
of unnatural leucines in GBP152 and GRPs, the pQE70 vector with GBP152 or GRP1 or 
GRP2 was transformed into E. coli leucine auxotrophic strain. The protein expression 
was then achieved by medium shift method165, 178, where the cells are grown in a minimal 
medium supplemented with salts, glucose and all 20 amino acids then the cells are 
washed and resuspended in minimal medium supplemented as before but lacking the 20th 
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amino acid which will be replaced by its unnatural analogue. The cells are starved for the 
20th amino acid and then the unnatural amino acid is added to the medium causing the 
cells to forcefully incorporate the amino acid in the protein. The cells are harvested by 
centrifugation and then purified using nickel affinity due to the presence of six histidine 
tag in the plasmid. To confirm the incorporation of unnatural amino acids, the unnatural 
GRPs were analyzed by LC-ESI-MS-MS. The difference in protein mass obtained 
confirmed the incorporation of the unnatural amino acids (Table 4.1). 
Previously we demonstrated that GBP152 chemically conjugated to fluorescent probes 
such as N-[2-(1-maleimidyl)ethyl]-7-(diethylamino)coumarin-3-carboxamide (MDCC) 
not only can bind to glucose, but also causes a modulation of the probe’s fluorescence 
directly proportional to the concentration of glucose.10 In a similar manner, 
GBP152/GRPs-FL/FW were covalently attached to MDCC and the effect of glucose on 
the fluorescence intensity of the probe was studied. The glucose binding activity of 
GBP152-FW/FL, GRP1-FW/FL and GRP2-FW/FL was then determined in solution by 
incubating the unnatural proteins with glucose solutions. The dose response curves for 
the unnatural proteins with FW and FL are shown in Figure 4.2a and 4.2b, respectively. 
A change in the fluorescence was observed with different concentration of glucose, 
suggesting that the incorporation of fluorinated tryptophan and leucine did not affect the 
glucose binding of the unnatural proteins. Apparent Kds were determined to be 5.4 x 10
-5 
M, 2.02 x 10-6 M, 4.1 x 10-6 M, 7.5 x10-4 M, 1.9 x 10-4 M and 1.8 x10-4 M for GBP152-
FL, GBP152-FW GRP1-FW, GRP2-FW, GRP1-FL and GRP2-FL respectively. It is also 
observed that proteins with unnatural trytophan demonstrate lower detection limits 
compared to the protein with unnatural leucine.  
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Table 4.1 Mass spectrometry analysis of trypsin digest of GBP152-FW/FL and GRPs-
FW/FL 
Protein Peptide Fragments Mass in 
GBP 
Mass in 
GRP 
Delta 
Mass 
GBP152-
FW 
TEQLQLDTAMWDTAQAK 1949.92 1966.91 16.99 
GAADGTNWK 918.42 936.41 17.99 
HWAANQGWDLNK 1438.67 1474.66 35.99 
GBP152-
FL 
DGQIQFVLLK 1160.67 1267.59 106.92 
ESGIIQGDLIAK 1243.69 1297.21 53.52 
ATFDLAK 765.414 818.32 52.91 
 
GRP1-FW 
GAADGTNWK 918.42 936.41 17.99 
MDAWLSGPNANK 1303.61 1320.59 16.98 
TEQLQLDTAMWDTAQAK 1949.92 1966.91 16.99 
 
GRP2-FW 
HWAANQGWDLNKDGQIQFVLLK 2600.34 2616.30 15.96 
MDAWLSGPNANK 1303.61 1320.59 16.98 
TEQLQLDTAMWDTAQAK 1949.92 1966.91 16.99 
 
GRP1-FL 
TEQLQLDTAMWDTAQAK 1949.92 2056.72 106.83 
HWAANQGWDLNKDGQIQFVLLK 2600.34 2742.08 141.74 
NLADGK 617.32 670.55 53.23 
 
GRP2-FL 
DGQIQFVLLK 1160.67 1267.49 106.82 
HWAANQGWDLNKDGQIQFVLLK 2600.34 2742.08 141.74 
QNDQIDVLLAK 1256.68 1363.51 106.83 
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Figure 4.2 Dose response curves for glucose employing proteins with (a) FW (b) FL. 
Data are the average of ± one standard deviation (n=3). Relative standard deviations at all 
concentrations are less than 10%. 
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The secondary structure of GBP152-FW/FL, GRP1-FW/FL and GRP2-FW/FL 
were then analyzed by far-UV CD spectroscopy at RT. The CD spectrum of GBP152-FW 
is similar to the reported CD spectrum of GBP,36 hence, indicating that the secondary 
structure of GBP152 is not altered by incorporation of unnatural tryptophans (Figure 
4.3a). This is further supported by the apparent Kds of both GBP152 and GBP152-FW in 
μM range. However, the CD spectrum of GBP152-FL (Figure 4.3b) is different from that 
of GBP152, as the bands at 222 nm and 208 are shifted and less intense for GBP152-FL. 
This suggests that the secondary structure of GBP152 is altered by incorporating 
unnatural leucines and, hence, explains the change in apparent Kd as compared to 
GBP152.  The CD spectrum of GRP1/2-FW (Figure 4.3a) reveals that the incorporation 
of fluorinated tryptophans in the trunctated proteins, i.e., GRP1/2 alter the secondary 
structure of protein as compared to the full length GBP152-FW. This can be explained 
again by both the position and intensity of bands at 222 nm and 208 nm. The band at 222 
nm for GRP1/2-FW is less pronounced than the corresponding band for GRP152-FW 
while the band at 208 nm in GBP152-FW is shifted towards lower wavelength (204 nm) 
in GRP1/2-FW. Also on comparing the secondary structure of GRP1/2-FW with the 
natural GRP1/242 it is evident that the band around 208 nm as seen in both the natural 
GRP1/2 is shifted to a lower wavelength of 204 nm in GRP1/2-FW, suggesting a 
decrease in alpha helical content. However, the CD spectrum of GRP1/GRP2-FL (Figure 
4.3b) suggests that the incorporation of fluorinated leucines in GRP1/2 does not alter the 
secondary structure as compared to GRP1/2, but is altered as compared to GBP152. 
The Thermal stability of the GBP152, GBP152-FW/FL, (Figure 4.4a) GRP1/2-
FW (Figure 4.4b) and GRP1/2-FL (Figure 4.4c) was determined by temperature-induced
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Figure 4.3 Secondary structure of proteins as determined by far-UV Circular Dichroism 
spectroscopy at room temperature. (a) GBP152-FW and GRP1/2-FW (b) GBP152-FL 
and GRP1/2-FL. 
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Figure 4.4 Thermal stability as determined by Circular Dichroism spectroscopy at 222 
nm. (a) GBP152, GBP152-FW and GBP152-FL (b) GRP1/2-FW (c) GRP1/2-FL. 
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CD changes at 222 nm. On comparing the thermal stability of the unnatural amino 
acid incorporated GRPs with the reported natural amino acid containing GRP1/242 , the 
GRP1/2-FW/FL show enhanced thermal stability.  Also the thermal stability of GBP152- 
FW/FL was enhanced as compared to GBP152. The melting temperatures, Tm, were 
determined to be 47 ⁰C, 66.1 ⁰C, 58.9 ⁰C, 41.0 ⁰C, 43.1 ⁰C, 65.3 ⁰C and 56.5 ⁰C for 
GBP152, GBP152-FL, GBP152-FW, GRP1-FW, GRP2-FW, GRP1-FL and GRP2-Fl 
respectively. Further, incorporation of fluorinated leucines demonstrated a larger increase 
in melting temperature as compared to fluorinated tryptophans. It is also observed that 
increase in Tm can be correlated to the number of leucines/tryptophans in the protein. 
GRP1 has 21 leucines and GRP2 has 19 leucines.  GRP2-FL, which has a total of 6 
fluorines less than GRP1-FL, has a Tm that is lower by 10 ⁰C than GRP1-FL. However, 
GRP1/2-FW have similar Tm as there is a difference of only one fluorine in the structure 
of the two proteins. 
 
CONCLUSIONS 
In summary, we illustrated a method to incorporate unnatural amino acids into 
glucose recognition proteins to alter their stability and properties. The global 
incorporation of fluorinated tryptophans and fluorinated leucines in the proteins affect the 
secondary structure of the proteins when compared to the secondary structure of GBP152 
but the ability to bind to glucose is not compromised. More importantly, FL and FW 
enhance the thermal stability of the sensing proteins. The enhanced thermal stability and 
altered Kds of these newly prepared GRPs makes them especially suited for long-term 
92 
 
glucose sensing applications in a variety of platforms and devices179. Moreover, it paves 
the way for the design and preparation of other binding proteins with tailor-made 
characteristics for a variety of biotechnology applications.  
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CHAPTER FIVE 
 
REAGENTLESS FIBER OPTIC BIOSENSOR FOR THE CONTINUOUS 
MONITORING OF GLUCOSE 
 
INTRODUCTION 
Diabetes affects millions of people worldwide resulting in a series of long term 
health consequences, including cardiovascular diseases180-182, neuropathy183, 184 and 
blindness.185, 186 Management of diabetes has initiated an urgent need for the close control 
of glucose in body fluids. The invention of a glucose self-monitoring device in 1971 
revolutionized modern diabetes care by allowing diabetics to live better lives though 
greater control of their diabetes.187  In-vivo monitoring of glucose levels, therefore, plays 
an important part in the management of diabetes. The current gold-standard method for 
measuring blood glucose is the finger prick method, which involves detection with a 
glucose biosensor. Hyperglycemia is also related to increased in-hospital mortality and 
morbidity in patients with cardiovascular diseases.188, 189 However, studies have indicated 
that there is a need for monitoring blood glucose levels in not only diabetics but non-
diabetic in-hospital patients.190 Attempts have been made for tight control of blood 
glucose levels in-hospital patients via point-of-care (POC) devices and have 
demonstrated a decrease in morbidity, mortality, and other complications for patients in 
critical care conditions.191-193 Most of the commercial glucose monitoring devices utilize 
electrochemical signal transduction based on the enzymatic activity reaction of either 
glucose oxidase194-196 or glucose dehydrogenase.197 However, these devices suffer from a 
series of drawbacks such as the presence of interferences in the blood, poor control of 
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activity due to variation in oxygen levels, and electrode fouling.198 Another limitation 
related to poor sensitivity of the glucose sensors in the hypoglycemic range198 and the 
somewhat limited stability of the proteins used as the recognition elements.199 Reports 
regarding the elevation of blood glucose levels and hence, worsening glycemic control in 
patients with diabetes under stress due to hypothermia, sepsis, etc. have underscored the 
need for a more accurate and stable continuous glucose monitoring device.200   
Dexcom’s SEVEN+ and Medtronic’s MiniMed Guardian are among the few 
continuous glucose monitoring devices available in the market. These devices measure 
subcutaneous glucose electrochemically in interstitial fluid. Yet, they suffer from 
problems such as substantial sensor drift and poor reliability.201 Given the above 
limitations it is not surprising that there is still a demand for glucose biosensors that are 
stable over time, can perform at temperatures covering all physiological thermic states, 
and are capable of sensing glucose at hypoglycemic, normal and hyperglycemic ranges.  
To that end, the design and development of fluorescence-based glucose sensor is 
reported. The sensor consisting of the use of a mutant of the Glucose/Galactose Binding 
Protein, GBP152, or unnatural amino acids incorporated GBP152 or unnatural amino 
acids incorporated truncated fragments of GBP 152, referred to as Glucose Recognition 
Proteins (GRPs) as the sensing element, which is covalently attached within an optically 
transparent acrylamide hydrogel immobilized on the tip of an optical fiber for detection 
of glucose. 
GBP of Escherichia coli is a periplasmic binding protein that binds glucose with 
high affinity (KD= 0.2 μM)
202 and is an attractive candidate for the development of 
glucose biosensors.203, 204 The mature GBP is a 33 kDa36 ellipsoidal protein and consists 
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of two distinctly similarly folded globular domains which are connected to each other by 
three peptide segments. The sugar binding site is located in a cleft formed between the 
two domains of the protein.39 The binding of glucose is accompanied by a conformational 
change that affects the hinge region. In the open form of GBP (absence of glucose), the 
two domains are far apart and the cleft is exposed to the solvent, while in the closed form, 
the glucose is engulfed within the cleft.39 GBP mutants with fluorophores in or near the 
binding pocket have been successfully employed for the development of reagentless 
glucose fluorescent biosensors by us and others.8, 10 GBP 152 was chosen as recognition 
element in our sensor because it has been previously reported by our group that this 
mutant when labeled with a fluorophore and in the presence of glucose undergoes a 
quenching of 30 % in its fluorescence intensity, thus making it ideal for the development 
of biosensors.  
GRPs are obtained by incorporating unnatural amino acids into the structure of 
GBP and its truncated fragments. In an attempt to design glucose sensing proteins with a 
minimum structure of GBP required for maintaining its affinity to glucose we have 
previously  truncated GBP into two fragments.42 These fragments are referred to as GRP1 
and GRP2 throughout the manuscript. GRP1 and GRP2 (collectively GRP1/2) have 
demonstrated affinity to glucose. GRP1/2 have been assumed to bind glucose in a similar 
manner to GBP. Further labeling GRP1/2 with a fluorescent probe has enabled 
fluorescence based glucose sensing in glucose solutions. It has been previously 
demonstrated that unnatural amino acids, 5-Fluorotryptophan (FW) and 5,5,5-
Trifluoroleucine (FL),  can be incorporated in GBP178 and GRP1/2 utilizing the global 
incorporation method. Incorporation of fluorinated amino acids into the structures of 
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GBP/GRP1/GRP2 have resulted in altered glucose binding affinities and enhanced 
thermal stability.  
The fluorescence based-biosensor was developed by covalent attachment of the 
fluorophore N-[2-(1-maleimidyl)ethyl]-7-(diethylamino)coumarin-3-carboxamide, 
MDCC  in GBP152/GRPs-FW/FL. Further, the MDCC-labeled protein was immobilized 
within the hydrogel on the tip of an optical fiber (Figure 5.1).  A hydrogel was employed 
to allow for high loading of the protein, and also to incorporate a diffusion barrier capable 
of shifting the detection range of GBP/GRPs-FW/FL from the micromolar to the 
milimolar range, which is necessary for in vivo glucose detection in hypoglycemic, 
normal, and hyperglycemic ranges. The response of the fiber optic glucose biosensor was 
evaluated in standard glucose solutions, in human serum and in pig blood, by monitoring 
the changes in fluorescence intensity of the probe. The response of the sensor was also 
studied at different temperatures, 35.5 ⁰C – 42 ⁰C, to reflect physiological situations 
ranging from hypothermia to hyperthermia. 
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Figure 5.1 Schematic of a fiber optic biosensor for glucose. GBP labeled with a 
fluorophore is covalently attached to the hydrogel and the hydrogel is immobilized on the 
tip of the optical fiber connected to a readout device. 
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EXPERIMENTAL PROCEDURES 
Materials 
Luria Bertani (LB) medium was purchased from Fischer Scientific (Fair Lawn, 
NJ). Ampicillin sodium salt, anhydrous calcium chloride, acrylic acid, acrylamide, 2,2-
Diethoxyacetaphenone, N,N′-Methylenebis(acrylamide), 3-(Trimethoxysilyl)propyl 
methacrylate (MPTS), tetracycline and human serum were purchased from Sigma-
Aldrich (St. Louis, MO). Imidazole was purchased from J.T. Baker, Inv. (Phillipsburg, 
NJ). Isopropyl-β-D-thiogalactoside (IPTG) was purchased from Gold Biotechnology, Inc. 
(Houstan, TX). The Bradford protein assay kit was purchased from Bio-Rad laboratories, 
Inc. (Hercules, CA). Sodium Dodecyl Sulfate (SDS) was purchased from Curtin 
Mathesin Scientific, Inc. (Houstan, TX). pQE70, QIAprep Spin Miniprep kit and Nickel-
NitriloTriAcetic acid (Ni-NTA) agarose was purchased from Qiagen (Valencia, CA). Tris 
glycine SDS Page gels and 7-diethylamino-3-((((2-maleimidyl)ethyl-
amino)carbonyl)coumarin (MDCC) and  Reagents required for TOPO TA cloning were 
purchased from Invitrogen (Carlsbad, CA). D-Glucose, anhydrous was purchased from 
Spectrum (New Brunswick, NJ).) Optical fiber with core diameter of 200 µm was 
obtained from Ocean Optics Inc. (Dunedin, FL).HEPES was purchased from VWR 
International (Bridgeport, NJ). All solutions were prepared using deionized reverse 
osmosis (MILL-Q Water purification System, Millipore, Bedford, MA) water. Swine 
whole blood was purchased from Innovative Research (Southfield, MI), 1-ethyl-3-(3-
dimethylaminopropyk)carbodiimide hydrochloride (EDC) and N-Hydroxysuccinimide 
(NHS) was purchased from Thermo Scientific (Waltham, MA). PFU Ultra II fusion HS 
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polymerase and other reagents required for PCR were purchased from Agilent. T4 DNA 
ligase was purchased from Promega (Madison, WI). 
Apparatus 
Cell cultures were grown on orbital shaker from Forma Scientific (Marrietta, OH) 
and Beckman J2-MI centrifuge (Palo Alto, CA) was used for harvesting the cells. 
GBP152 was obtained by lysing the cells with 550 sonic dismembrator from Fisher 
Scientific. Varian Carry Eclipse fluorescence Spectrophotometer was used for 
fluorescence study of GBP152 in solution. UVGL-58 hand held UV lamp for 
polymerization of hydrogel was obtained from UVP (Upland, CA). A thermal water 
circulator from Polyscience (Niles, IL) was used for temperature study. USB4000 
Miniature Fiber Optic Spectrometer, obtained from Ocean Optics (Dunedin, Fl), was used 
for fluorescence measurements of hydrogel. 
 
Construction of plasmid pSDGBP 
The polymerase chain reaction (PCR) was performed to introduce a SphI 
restriction site at the 5’ end and a BamHI site at the 3’ end of the GBP152 coding 
sequence. pSD50210 was used as a template for PCR with PFU Ultra II fusion HS 
polymerase and primers in a 30-cycle PCR. The primers used were GBPforSph: 5’-
GAGGCATGCTTGATACTCGCATTGGTGTAACAATC-3’ and GBPrevBam: 5’-
CTCGGATCCTTTCTTGCTAAATTCAGCCAGGTTGTC-3’. Cycle conditions were 95 
°C x 5 min followed by 30 cycles of 95 °C x 30 s, 55 °C x 30 s, 72 °C x 1 min, 72 °C x 7 
min, then Taq polymerase and dNTPs were added to the reaction mixture for TA cloning, 
followed by 72 °C x 15 min. Reaction was run on TAE 1% agarose gel and the PCR 
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product was cut out and extracted from the gel. The extracted product was TOPO TA 
cloned following the method provided with the kit from Invitrogen. TA clones were 
grown in LB medium and then screened for the insert of the coding sequence for GBP152 
by digesting with SphI and BamHI. The digested product was run on TAE 1% agarose 
gel and then extracted from the gel using QIAprep Spin Miniprep kit. The extracted 
product was then ligated into SphI and BamHI sites of pQE70 and thus resulting in 
plasmid pSDGBP. Ligation was carried out overnight at room temperature using T4 
DNA ligase. pSDGBP was then transformed into TOP10F' cells using a modified 
rubidium chloride method.205 
 
Expression and Purification of GBP and GRPs-FW/FL 
For expression of GBP mutant with Cys at position 152, 10 ml LB broth 
containing 100 μg/ml ampicillin and 12 μg/mL tetracycline was inoculated with a single 
E.coli colony containing the pQE70 vector with GBP152. The culture was grown 
overnight (17-18 h) at 370C at 250 rpm. Next day 500ml LB broth containing 100 μg/ml 
ampicillin and 12 μg/ml tetracycline was inoculated with the 10 ml of the overnight 
culture and was grown at 37 0C at 250 rpm to an OD600 of 0.2. The culture was then 
grown at room temperature at 250 rpm to an OD600 of 0.4. The GBP expression was then 
induced by adding IPTG to 1mM final concentration. The culture was then allowed to 
grow for 3 h at room temperature at 250 rpm and the cells were then harvested by 
centrifugation at 12,000 rpm for 15 min at 4 0C.  
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Plasmid pQE70 with GRP42, 178 and pLacI were co-transformed into the E.coli 
tryptophan auxotroph ATCC #27873 for expression of GRPs-FW. Plasmid pQE70 with 
 GRP42, 178 were transformed into the E.coli leucine auxotroph HB101F΄ for 
expression of GRPs-FL. Protein expression was performed using medium shift 
method165. A single freshly transformed colony was used to inoculate 5 mL of M9 media 
supplemented with 0.4% glucose, 1 mM MgSO4, 0.1 mM CaCl2, 1 mM Thiamine, 0.1 
volume of a solution containing 0.01% (w/v) each of 19 amino acids (-Leu/ or -Trp), 40 
µg/mL Leu/ or Trp and 100 µg/ml ampicillin. This culture was allowed to grow overnight 
at 37 0C, 250 rpm. 500 mL culture containing the same ingredients was inoculated with 
the overnight grown 5 mL culture. This culture was then grown till the optical density 
(OD600) was ~0.5- 0.6. The cells were then centrifuged at 10,000 rpm for 10 min, 25 
0C, 
the supernatant was discarded and the cells were resuspended in a 0.9% NaCl solution for 
washing, and this was repeated three times. The cells were then resuspended in 500 mL 
M9 minimal media which was supplemented with 0.4% glucose, 1 mM MgSO4, 0.1 mM 
CaCl2, 1 mM Thiamine, 0.1 volume of a solution containing 0.01% (w/v) each of 19 
amino acids (-Leu/ or -Trp), 100 µg/mL ampicillin, and grown at 37 0C for 30 min to 
further deplete leucine. 1 mM Isopropyl β-D-1-thiogalactopyranoside, IPTG was then 
added with 0.1 mM of 5,5,5-fluoroleucine/ or 5-fluorotryptophan to the culture and was 
grown overnight at 37 0C. 
  For the extraction of GBP/GRPs-FW/FL, the cell pellet was resuspended in 30 
mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and the 
cytoplasmic GBP was released from the cells by sonication (5 min cycle, 10 sec ON and 
10 sec OFF). The sonicated cells were removed by centrifugation at 12,000 rpm for 20 
102 
 
min at 4 0C and the supernatant was collected. 2ml of Ni-NTA agarose resin were added 
to the cell lysate, which was then incubated at 4 0C on a rotor for 1 h. The cell lysate with 
the resin was poured in a column and the unbound resin was allowed to flow through. 
The column was then washed with 30 mL of wash buffer (50 mM NaH2PO4, 300 mM 
NaCl, 20 mM imidazole, pH 8.0). The protein was eluted by adding the elution buffer (50 
mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0) to the column and 1 ml 
fractions were collected. The purity of proteins was determined by SDS-PAGE, using 
12% acrylamide gels that were stained with Commassie blue. The purified protein was 
dialyzed against three changes of 10 mM HEPES, 0.2 mM CaCl2, pH 7.0 over 12 h. The 
purified protein concentration was determined by Bradford assay. 
Labeling GBP/GRPs-FW/FL with MDCC 
DTT was added to the purified protein solution to a 2 mM final concentration.  
The resulting solution was incubated at 4 °C to reduce any disulfide linkages that may 
have formed between two protein molecules. After the reduction was complete DTT was 
removed from the protein solution by running the sample through Microcon Ultracel 
YM-10 and resuspending the obtained protein concentrate in 10 mM HEPES, 0.2 mM 
CaCl2, pH 7.0. The conjugation of the fluorophore to the protein was achieved by mixing 
1 equivalents of the protein with 10 equivalents of MDCC. The resulting solution was 
incubated in dark at 4 ⁰C overnight. Then the excess fluorophore was removed from the 
MDCC labeled protein by dialyzing the protein solution against six changes of 10 mM 
HEPES, pH 7.00, containing 0.2 mM CaCl2, over a period of 24 h.  
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Fluorescence study of GBP152-MDCC in solution 
The excitation and emission wavelengths of MDCC were 425 nm and 475 nm, 
respectively. The concentration of labeled proteins used in the fluorescence studies was 1 
X 10-7 M. The MDCC conjugates were incubated with various glucose concentrations for 
15 min. All measurements were done at RT in quartz cuvettes in a sample volume of 200 
µL. 
 
Conjugation of MDCC-labeled GBP/GRPs-FW/FL with Acrylic acid 
For the conjugation reaction, 10 equivalents of acrylic acid were added to a 
solution containing 2 mM EDC and 5 mM NHS. This mixture was then incubated at 
room temperature for 2 h with stirring. Then, one equivalent of MDCC labeled proteins 
in 10 mM HEPES, 0.2 mM CaCl2, pH 7.0 was added to the EDC and NHS treated acrylic 
acid and incubated in dark at 4 ⁰C overnight. The acrylic acid conjugated protein was 
separated from the free acrylic acid, EDC, and NHS by running the sample through a 
centrifugal filter device (Microcon Ultracel YM-10). The obtained protein was then 
resuspended in 10 mM HEPES, 0.2 mM CaCl2, pH 8.0. 
Preparation of Hydrogel Precursor Solution and Optical Fiber Surface Modification 
A hydrogel precursor solution was made from the combination of 8 uL of (1.125 
mg acrylamide and 4.125 ug N,N ethylenebisacrylamide in 1 ml), 4 μL 10% glycerol, 9 
μL of 1.2 X 10-4 M GBP-MDCC-Acrylic acid, and 0.5 μL 2,2-diethoxyacetaphenone. 
The fiber was cleaned by immersing in 1:1 concentrated HCl: MeOH for 30 min and then 
rinsed in deionized water and immersed in concentrated H2SO4 for 30 min at room 
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temperature. It was rinsed again by immersing deionized water for 10 min followed by 
rinsing with ethanol. The fiber was then silanized by immersing in MPTS (3-
(Trimethoxysilyl)propyl methacrylate) for 1 h at room temperature and then air dried. 0.3 
µL hydrogel precursor solution was deposited on the tip of silanized fiber and 
polymerized under UV for 30 min. The prepared fibers were stored at 4 ⁰C till further 
use. 
Optimization of sensor response time 
The optical fiber with the immobilized GBP152 hydrogel was immersed in 2 mL 
of glucose solutions of concentrations ranging from 2 mM to 20 mM in buffer for 30 min. 
The sensor response i.e. the fluorescence was measured after 1 min, 5 min and 30 min for 
each glucose solution. 
Study of the effect of the length of fiber on sensor response 
Two different optical fibers with lengths of 38 cm and 45 cm were used. Hydrogel 
containing GBP152-MDCC was immobilized on tip of each silanized fiber. The fibers 
with hydrogel were then dipped in different concentrations of glucose separately and the 
fluorescence from the sensor was measured. 
Sensor response 
The response of the fiber based GBP152/GRPs-FW/FL hydrogel sensor was 
determined by immersing the tip of the hydrogel coated fiber in 2 ml glucose (2 mM – 20 
mM) solutions containing 10 mM HEPES and 0.2 mM CaCl2 with pH 8.0. The hydrogel 
was washed with 2 mL of buffer for 2 min after each concentration of glucose. The 
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fluorescence intensity of the hydrogel with MDCC labeled proteins at 475 nm, excited by 
the optical fiber at 425 nm, was recorded by Ocean Optics Spectrometer. Similarly, the 
sensor response was also determined in human serum and in pig blood, both spiked with 
different glucose concentrations (2 mM – 20 mM). The reversibility of the sensor was 
determined by immersing the hydrogel coated fiber in 2 ml glucose solutions (20 mM – 2 
mM) as described above. Response of the sensor was also determined at different 
temperatures (35.5 ⁰C, 37 ⁰C, room temperature and 42.5 ⁰C) by immersing the fiber tip 
with hydrogel in 2ml glucose solutions in glass vials kept in thermal water cycler used to 
maintain the temperature. All the experiments were performed in dark. 
 
RESULTS AND DISCUSSION 
The glucose biosensor reported herein is based on the use of GBP/GRPs-FW/FL 
immobilized into a hydrogel network, which in turn is positioned at the tip of an optical 
fiber.  The basis for the response of the glucose biosensor is the conformational changes 
that GBP/GRPs undergo upon binding to glucose.  Therefore, in order to investigate and 
correlate the changes in conformation of protein with glucose concentrations a signal 
generating molecule into the system capable of reporting such changes was required to be 
incorporated into the protein structure.  For that, a genetically engineered mutant of wild-
type GBP, with a unique Cys at position 152 (GBP152), was used to obtain designer 
GRPs for selectively attaching an environment sensitive fluorophore, MDCC, into the 
proteins.42  It has been previously shown by our group that this mutant when labeled with 
MDCC, in the presence of glucose presents a 30% decrease in the intensity of the 
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fluorescence signal.10 In order to purify the protein using an easy method such as a Ni-
affinity column, the GBP152 coding sequence was removed from pSD502 and ligated 
into vector pQE70 that encodes for a histidine tag at the C-terminus of the protein. For 
regulating the expression of GBP152, plasmid pSDGBP was transformed into TOP10F' 
cells. However, for expression of GRPs with unnatural amino acids plasmid pSDGBP 
was transformed into the respective auxotrophic strain of E. coli. The purified proteins 
were first analyzed by SDS-PAGE and concentration was determined by employing the 
Bradford assay prior to labeleing of the proteins with MDCC using the thiol chemistry to 
the Cys in the proteins.  
The response of GBP152-MDCC in solution was evaluated by incubating it with 
different concentrations of glucose solutions in 10 mM HEPES, 0.2 mM CaCl2, pH 8.0 
and measuring the fluorescence of the samples. Figure 5.2 shows that the fluorescence of 
GBP152-MDCC decreases with the increase in concentration of glucose. The response of 
GRPs-FW/FL is discussed in Chapter 4.  
The next step involved crosslinking the fluorophore-labeled GBP152/GRPs-
FW/FL within an acrylamide optically transparent hydrogel.  This hydrogel not only 
allows for the loading of larger amounts of protein, but it also serves as a diffusion 
barrier.  Furthermore, incorporation of the proteins in a hydrogel allows for the detection 
range of glucose in physiologically relevant milimolar range. MDCC-labeled proteins 
were conjugated to acrylic acid by employing well-established protocols of EDC/ NHS 
mediated activation of amines in amino acids to label the lysines residues in the proteins 
with acrylic acid.  This reaction results in the formation of GBP152/GRPs-FW/FL-acrylic 
acid conjugates, thereby, functionalizing GBP152/GRPs-FW/FL with many allyl groups, 
107 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Fluorescence study of GBP152-MDCC in presence of glucose. Data are the 
average of ± one standard deviation (n=3). Relative standard deviations at all 
concentrations are less than 10%. 
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which can be covalently attached within the hydrogel. Although there are 29 Lys in the 
sequence of glucose binding protein (GBP) eight are partially buried (K11, 92, 104, 147, 
189, 227, 270, and 289) and an additional 6 form ion pairs (salt bridges) with acidic 
residues, including K113 with D111; K191 with D179; K79 with D53; K125 with D299; 
K169 with D121, K263 with D267 (Figure 5.3a). All these interactions would hinder 
their accessibility to labeling. Therefore only the more flexible and exposed lysines will 
be readily labeled with acrylic acid. This accounts for the GBP/GRPs to retain the 
glucose binding ability. 
Furthermore, the optical fiber was silanized with MPTS, which also results in 
functionalizion of the fiber with allyl groups. This was followed by polymerization 
between the protein-acrylic acid, with acrylamide (forming the polymer backbone), using 
bisacrylamide as the crosslinking agent, and 2,2-Diethoxyacetaphenone as the initiator.  
The resulting polymer crosslinks to the surface of the fiber through the allyl groups when 
it is placed on the silanized fiber and subjected to UV light to obtain covalent 
immobilization of the hydrogel on the tip of the silanized fiber (Figure 5.3b).   
The MDCC-labeled protein covalently immobilized within the hydrogel matrix 
demonstrated its capability to emit fluorescence at 475 nm after excitation of the MDCC 
fluorophore at 425 nm (Figure 5.4). To ensure that the protein is covalently bound within 
the hydrogel and does not leach into the solution once the tip of the optical fiber is 
immersed in buffer, the fluorescence of the GBP152 hydrogel in buffer as well as the 
fluorescence of the buffer (in which the hydrogel is immersed) was measured every 10 
min. Table 1 shows that both, the fluorescence of the hydrogel and that of the buffer, 
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Figure 5.3 (a) Space filled presentation of GBP. Residues other than lysine are colored as 
blue for nitrogen, white for carbon and red for oxygen. The partially buried lysines 
are green, the ion-pair forming ones are purple (with their acidic residue partner colored 
in cyan), and the exposed ones are orange. (b) Schematic of the steps involved in the 
immobilization of hydrogel containing covalently attached fluorescent GBP/GRPs. 
a 
b 
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Figure 5.4 Excitation and emission wavelengths (425 nm and 475 nm respectively) of 
MDCC labeled GBP152 immobilized on the tip of a fiber in an optically transparent 
hydrogel. 
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Table 5.1 Leaching studies to determine the covalently bound fluorophore labeled 
GBP152 within the acrylamide hydrogel. 
Time 
(min) 
Fluorescence of 
Buffer 
Fluorescence of 
Hydrogel 
0 19.22 583.64 
10 19.32 587.18 
20 18.64 583.99 
40 19.66 589.65 
60 20.17 588.08 
80 19.07 587.36 
100 18.58 588.41 
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does not change over a period of 100 min. This confirms that the fluorophore-labeled 
protein is covalently bound and contained within the hydrogel. No leaching of the 
fluorophore bound-protein is observed. 
For the optimization of response time of the sensor, the sensor was immersed in 
buffer solutions containing glucose in mM concentrations and the fluorescence change 
recorded over a period of 30 min. The response time for the sensor was determined to be 
1 min, as the observed change in the fluorescence intensity in the presence of glucose was 
completed within 1 min (Figure 5.5) 
The reversibility of the sensor was determined by measuring the change in 
fluorescence when the sensor is immersed in buffer with increasing glucose 
concentrations (2 mM -20 mM) followed by decreasing glucose concentrations (20 mM – 
2 mM).  Figure 5.6 shows that the fluorescence signal decreased with the increase in 
glucose concentration to almost the same extent as the increase in signal with the 
decrease in glucose concentration. Change in the fluorescence intensity observed when 
going from low to high glucose concentrations is the same as the change in fluorescence 
intensity observed from high to low glucose concentrations. While the signal generated 
by the biosensor did not show 100% reversibility, still it returns to the baseline 
completely. This can be explained due to the increase in the glucose concentration within 
the buffer upon release of glucose from the hydrogel in going from high to low glucose 
concentrations.  
The effect of the length of optical fiber on sensor response was studied by 
immobilizing the GBP152 hydrogel precursor solution on two different optical fibers  
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Figure 5.5 Sensor response at different time intervals. Data are the average of ± one 
standard deviation (n=3). Relative standard deviations at all concentrations are less than 
10%. 
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Figure 5.6 Sensor reversibility. Data are the average of ± one standard deviation (n=3). 
Relative standard deviations at all concentrations are less than 10%. 
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with different lengths (Figure 5.7). The sensor response for each fiber was then 
determined by measuring the fluorescence intensity of the covalently immobilized protein 
hydrogel when dipping the hydrogel in glucose solutions. It was observed that the shorter 
fiber (38 cm) showed higher fluorescence intensity at each concentration of glucose than 
the longer fiber (45 cm). This can be explained by the loss of light as it travels through 
the fiber. 
The sensor response was also studied over a period of three days. After three days 
it was observed that the mechanical integrity of the hydrogel was starting to fade. For 
this, a GBP hydrogel was immobilized onto the tip of a silanized fiber and its response 
was measured during three consecutive days as described previously in different glucose 
solutions. The fiber was stored at 4 °C in buffer and in the dark after measuring the 
response each day at 37 °C. The results (Figure 5.8) show that the sensor response was 
not affected by storage in solution. The immobilized protein was still active and its 
binding to glucose was not affected by storage and time for at least three days. 
Response of the sensor was studied in buffer by immersing the silanized fiber 
with fluorophore labeled GBP152/GRPs-FW/FL hydrogel immobilized on the tip, in 
glucose solutions of concentrations within mM ranges. As shown in Figure 5.9a, 5.9b, 
and 5.9c, the fluorescence intensity decreases with the increase in glucose concentrations. 
The binding of glucose to GBP152/GRPs-FW/FL causes a change in the 
microenvironment of the glucose binding site that is manifested by an alteration in the 
fluorescence properties of the fluorophore in a directly proportional manner to the 
concentration of glucose present in the sample. The development of the hydrogel 
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Figure 5.7 Response of two different sensors with GBP152 immobilized within the 
hydrogel. The sensors differ in the length if optical fiber used. Data are the average of ± 
one standard deviation (n=3). Relative standard deviations at all concentrations are less 
than 10%. 
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Figure 5.8 Response of hydrogel based fiber optic sensor with covalently immobilized 
GBP152 on three consecutive days. Data are the average of ± one standard deviation 
(n=3). Relative standard deviations at all concentrations are less than 10%. 
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Figure 5.9  Fluorescence study of fiber optic sensor in physiologically relevant glucose 
concentrations (a) GBP152 (b) GRPs-FW (c) GRPs-FL. Data are the average of ± one 
standard deviation (n=3). Relative standard deviations at all concentrations are less than 
10%. 
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biosensor allows the detection of glucose in the desired physiological mM range by 
incorporation of a diffusion barrier provided by the hydrogel matrix. 
In order to study the performance of the GBP152/GRPs-FW/FL sensor in 
physiological fluids, the sensor response was studied in human serum (Figure 5.10a and 
5.10b) and pig blood (5.11a and 5.11b). A quenching in the fluorescence signal was 
observed with the increase in glucose concentration, both in spiked human serum and pig 
blood for all the sensors. Since the initial glucose concentration in pig blood and human 
serum was 1.6 mM and 6.5 mM, respectively as determined by Free Style Lite (Abott) 
blood glucose monitoring system, human serum and pig blood were spiked to reach the 
glucose level upto 20 mM. The performance for GBP152/GRPs-FW/FL sensor was also 
evaluated by measuring its response at different temperatures such as RT, 37 °C and 42.5 
°C (Figure 5.12a-d and Figure 5.13a-c). The results obtained are those that we would 
expect given the demonstrated thermal stability of the GBP152/GRPs-FW/FL. Since the 
GBP152, GRP1-FW, and GRP2-FW have Tm at 47 ⁰C, 41.0 ⁰C, and 43.1 ⁰C 
respectively, the sensors incorporating these proteins showed very little change in 
fluorescence in the presence of different glucose concentrations at 42.5 ⁰C. However, 
GRP-FW178, GRP-FL178, GRP1-FL and GRP2-FL with Tm at 58.9 ⁰C, 66.1 ⁰C, 65.3 ⁰C, 
and 56.5 ⁰C respectively showed fluorescence quenching at both 37 ⁰C and 42.5⁰C. Thus, 
GRP-FW and GRPs-FL retain glucose binding activity at higher temperatures. Thus, the 
sensors incorporating designer proteins with enhanced thermal stability can be utilized 
for the monitoring of glucose within a range of temperatures including those in 
hypothermic and hyperthermic ranges. 
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Figure 5.10 Fluorescence study of fiber optic sensor in spiked human serum (a) GRPs-
FW (b) GRPs-FL. Data are the average of ± one standard deviation (n=3). Relative 
standard deviations at all concentrations are less than 10%. 
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Figure 5.11 Fluorescence study of fiber optic sensor in spiked pig blood (a) GRPs-FW 
(b) GRPs-FL. Data are the average of ± one standard deviation (n=3). Relative standard 
deviations at all concentrations are less than 10%. 
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Figure 5.12 Temperature study of GBP142 and GBP-FW sensor (a) GBP152 (b) GRP-
FW (c) GRP1-FW (d) GRP2-FW. Symbols represent  35.5 °C, and  42.5 °C. Data are 
the average of ± one standard deviation (n=3). Relative standard deviations at all 
concentrations are less than 10%. 
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Figure 5.13 Temperature study of GRPs-FL sensor (a) GRP-FL (b) GRP1-FL (c) GRP2-
FL. Symbols represent  35.5 °C, and  42.5 °C. Data are the average of ± one standard 
deviation (n=3). Relative standard deviations at all concentrations are less than 10%. 
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CONCLUSIONS 
The existing need for continuous glucose monitoring in diabetics as well as in-
hospital patients instigated the development of our fiber optic-based glucose monitoring 
systems. As previously mentioned, the currently available glucose sensing devices have a 
number of limitations. In addition to the devices described in this chapter others such as 
the,“GluCath”, an intravascular continuous monitor product from GluMetrics, Inc., is still 
in the developmental stages.206 GluCath is based on fluorescent derivatives of boronates. 
Although the product claims to be sensitive in hypoglycemic ranges, it suffers from some 
major limitations. These limitations arise from of the fact that boronic acid derivatives 
based-glucose sensors are known to be pH sensitive74 and to bind to glycosylated 
proteins.207, 208 Thus, these impose a challenge when using boronates to measure glucose 
in the clinic under physiological conditions. 
In this research fiber optic-based reagentless fluorescence biosensor for glucose, 
comprising of a miniaturized hydrogel that incorporates glucose binding protein,GBP152 
or designer glucose recognition proteins, GRPs-FW/FL were developed. Immobilizing 
the protein within the hydrogel network provides protection to the protein and worsens 
the detection limit to our advantage. Thus, enables the sensing of glucose in 
physiologically relevant mM ranges. The fiber optic glucose biosensors demonstrated a 
fast response time, ~ 1 min, at different physiological temperatures ranging from 35.5 °C 
to 42.5 °C. The biosensors are highly selective and sensitive to glucose. Moreover, the 
biosensors were capable of glucose detection in different samples, including human 
serum and pig blood, without any pretreatment of the sample. Thus, demonstrating its 
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sensitivity at physiological pH and its potential use in the monitoring of glucose as it 
overcomes the limitations of the existing glucose sensing systems. 
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CHAPTER SIX 
 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Protein Engineering is a valuable tool for manipulation of protein structure and 
hence, for better understanding of protein structure and function. Traditional design 
methods in protein engineering are based, among others, on direct evolution or rational 
design. In recent years, computational protein design methods have provided further 
insights into protein structure. Engineered proteins have found application in the 
development of sensing devices. Fluorescence-based sensing is a powerful tool utilized 
for the development of fast, reagentless, and non-invasive detection of analytes. Proteins 
have been engineered to fluoresce by either fusion of the non-fluorescing proteins with 
fluorescent proteins, conjugation of fluorescent molecules or incorporation of unnatural 
fluorescent amino acids.  In this work, we describe the development of designer proteins 
and their utilization for the development of fluorescence-based biosensors for glucose 
and universal biosensing systems for several biomolecules of interest. 
Chapter two and three describes the development of universal biosensing systems 
for the detection of biomolecules of interest. The biosensing system utilizes modified 
monoclonal antibodies. The non-canonical site in the variable region of antibodies near 
the antigen-binding site is modified and utilized for signal transduction. The non-
canonical site has been reported to covalently bind to nucleotides with azide 
functionality. Docking to this non-canonical site does not alter the antigen-binding ability 
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of the antibody. In an effort towards design of antibodies capable of sensing molecules 
for target analytes, the non-canonical site in the monoclonal antibody was covalently 
conjugated to a fluorophore labeled azido-nucleotide that acts as the reporter molecule of 
the biosensing element. This modification at the non-canonical site does not affect the 
antigen binding, which was demonstrated by testing the biosensing system for two 
different analytes. The first analyte employed in the proof of concept work was 
Interleukin 6. Interleukin 6 is a pro- and anti-inflammatory cytokine, whose 
concentrations is elevated in several disease states, including cardiovascular diseases. The 
second analyte of interest chosen for our work is Osteonectin, a salivary bone marker. 
The biosensing system thus developed is universal as it can be utilized for the detection 
of a variety of analytes depending upon the availability of monoclonal antibody against 
the analyte of interest. 
Future work with respect to the work described in Chapters Two and Three 
should include understanding the mechanism of response of the fluorescently labeled 
antibody when exposed to its corresponding ligand analyte.  Current studies showed a lag 
time in generating a response of the antibody when exposure to its ligand.   This could be 
due to a change in conformation of the antibody upon binding the ligand, or simply due 
to the time needed for difussion of the ligand into the binding pocket of the antibody.   To 
elucidate this mechanism, a time study of the response generated by a series of 
concentrations (lower than that employed in the study) of fluorescently labeled antibody 
to its corresponding antigen should be undertaken. This would provide an answer on 
whether the lag time is due to diffusion or hint toward a delayed conformational change. 
Future work can be further extended by developing detection systems utilizing the above 
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mentioned strategy for other biomolecules of interest. Some examples include cortisol, 
osteocalcin and melatonin. In our work we utilized ATP-modifed probes for conjugation 
of the fluorophore to the non-canonical site of the antibody. Other nucleotide probes 
wherein the fluorophore is conjugated to the probe not at the γ-phosphate of ATP, but 
rather covalently linked to the oxidized ribose can be utilized for labeling the antibody 
unconventional site. The effect of conjugating the fluorophore at this position might 
produce a fluorescence signal of similar or different intensity as in previous design and 
thus, provide a better understanding of the orientation of fluorophore within the non-
canonical nucleoside binding site. The effect of antigen-binding to the antibody can be 
then studied using these fluorescent probes. Further, it has been reported that the non-
canonical site has affinity for heterocyclic ring structures and, therefore, the use of other 
nucleotides, nucleosides and amino acids such as tryptophan should be explored as 
probes for the covalent attachment of the reporter fluorophore molecule. Also several 
other fluorophores can be conjugated to the nucleotide probes, allowing for a wider range 
of emission wavelengths of the reporter molecule.   
 Chapter four describes the global incorporation of unnatural tryptophan and 
unnatural leucine into the amino acid sequence of GBP of E coli and its truncated 
fragments. 5-Fluorotryptophan and 5,5,5-trifluoroleucines were incorporated separately 
in the protein by using a medium shift method wherein the bacteria is first grown in a 
medium enriched with all 20 amino acids, and then transferred to a medium lacking the 
20th amino acid, which is then replaced by its unnatural analogue. By utilizing this 
method we have been successful in replacing all the natural tryptophans or leucines by 
their unnatural analogues in the Glucose/Galactose binding protein (GBP) and its 
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truncated fragments (GRPs). The effect of incorporation of these unnatural amino acids 
on the secondary structure, glucose binding activity, and thermal stability of the proteins 
was studied. Circular dichroism spectroscopy in the UV region at room temperature 
demonstrated that the incorporation of 5-Fluorotryptophans in full length GBP does not 
affect the secondary structure of GBP. However, the incorporation of fluoroleucines in 
GBP does alter the secondary structure. Incorporation of either fluorotryptophans or 
fluoroleucines in truncated GBP fragments does affect the secondary structure of the 
proteins. This change in the secondary structure does not prevent the GRPs from binding 
to glucose. However, their glucose binding ability was altered as can be inferred from the 
apparent Kds of these unnatural proteins (GRPs) compared to natural GBP. The glucose 
binding ability of these unnatural proteins was determined by labeling the proteins with 
an environment sensitive fluorophore, MDCC, and generating dose-response curves for 
glucose and other sugars. All proteins utilized for incorporation of unnatural amino acids 
contained a unique cysteine that was conjugated to MDCC using the sulfhydryl group of 
cysteine. Further, thermal stability of the unnatural proteins was determined by far-UV 
circular dichroism spectroscopy. Incorporation of fluorinated tryptophans or leucines in 
the proteins demonstrated an increase in the thermal stability of the proteins.  
 The work described in Chapter four can be further extended by incorporating 
other unnatural amino acids that would confer these proteins with special properties and 
functionalities without diminishing their glucose binding capability. Some examples of 
unnatural amino acids that can be incorporated in the future include 
benzoylphenylalanine, p-azidophenylalanine and azidonorleucine, which can confer a 
photoreactive functionality to the protein that can be further harnessed for selective 
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modification of proteins for sensing purposes. Another example of unnatural amino acid 
that can be incorporated in these proteins is 2-Ferrocenylglycine, an electroactive non-
natural amino. The incorporation of an electroactive amino acid will allow for the further 
development of electrochemical sensor for glucose utilizing these unnatural electroactive 
proteins.  
 In this work, the proteins were labeled with a fluorophore for the development of 
optical sensors. A future improvement to this work would be the incorporation of a 
fluorescent amino acid within the structure of the proteins, which would result in 
genetically encoded fluorescent proteins.  An example of such an amino acid is 2-Amino-
3-(7-methoxy-2-oxo-2H-chromen-4-yl)propanoic acid, an alanine  analogue and a 
fluorotryptophan. Incorporation of these unnatural amino acids would confer inherent 
fluorescence to the proteins and, hence, these can be directly utilized for the development 
of optical sensors. 
 Chapters five describe the development of fiber optic-based glucose 
biosensors, wherein, the fluorophore-conjugated glucose recognition element, GBP or 
GRPs, was covalently immobilized within an optically transparent acrylamide hydrogel. 
GBP, as well as the unnatural amino acids incorporated GRPs, have a high affinity for 
glucose with Kds in the 10
-6 M to 10-5 M range. In an effort to develop a glucose 
biosensor that can detect glucose in physiologically relevant mM concentrations, the 
fluorescently labeled GBP/GRPs were encaptured within a hydrogel matrix.  The 
Hydrogel matrix serves several purposes as it provides for a hydrophilic, protein friendly 
environment, allows for high loading of the protein, and serves as a diffusion barrier 
capable of shifting the detection range of the proteins to the desired mM range. In our 
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work, the hydrogel was further immobilized on the tip of an optical fiber. The sensor 
response demonstrated reversibility at low-to-high glucose concentration ranges and 
viceversa. The ruggedness of the sensor was demonstrated by evaluating the sensor 
response during three consecutive days.  Further the sensor exhibited acceptable response 
in body fluids such as blood and serum and at physiologically important temperatures. 
Thus, the sensor performance suggests its potential use for use for in vivo glucose 
monitoring.  
Future work for improvement of the biosensing systems described in Chapters 
five could be accomplished by further enclosing the hydrogel within a dialysis membrane 
and attached onto the tip of the optical fiber. The dialysis membrane would help to retain 
the hydrogel integrity over longer periods of storage and use. In order to introduce an 
internal reference within the fiber optic sensor to eliminate background noise due to the 
variations in intensity of light, another fluorophore that is not sensitive to the 
environment can be labeled to the protein at a position that does not interfere glucose 
binding. Ratiometeric study of emissions of environment sensitive and non-environment 
sensitive fluorophores can then be performed. This single optical fiber optic based sensor 
can be used as a catheter for in vivo applications as such. However, a dual lumen catheter 
would extend its utility for in vivo applications, wherein, one lumen would contain the 
sensor, while another would contain a channel through which blood may be drawn, such 
that glucose readings from the same blood sample can be analyzed and compared by both 
the catheter and traditional methods. Further incorporation of more than one hydrogel 
with the glucose sensing element on different fibers bundled together can be utilized for 
extending the life of the sensor, as after the lifetime of one sensor has expired other 
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sensor could be used for glucose recognition in blood. Study of the functioning of the 
catheters in animal study would enable to determine the performance of the sensor in 
vivo.  
 In conclusion, antibody-based sensing system for universal detection of analytes 
of interest was successfully developed by labeling an inherent non-canonical nucleoside 
binding site with a fluorophore conjugated nucleotide probe. Docking the non-canonical 
site did not affect the antigen binding. The developed sensing system was demonstrated 
to be very selective due to the use of monoclonal antibodies. Successful development of 
glucose recognition proteins with enhanced thermal stability by incorporation of 
unnatural amino acids in to the structure of GBP and its truncated fragments has been 
reported. Further, application of the unnatural amino acid incorporated proteins for the 
development of fiber optic based biosensor for in vivo glucose monitoring has also been 
demonstrated.   
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